Urinary system์€ kidney(์‹ ์žฅ, ์ฝฉํŒฅ) / ureter(์š”๊ด€) / urinary bladder(๋ฐฉ๊ด‘) / urethra(์š”๋„) ๋กœ ๊ตฌ์„ฑ๋œ๋‹ค.

1. Normal Renal Anatomy & Function

  • ์‹ ์žฅ์€ โ€œnephronโ€์ด๋ผ๋Š” ๊ธฐ๋Šฅ์  ๋‹จ์œ„๋กœ ๊ตฌ์„ฑ๋œ๋‹ค.
  • ์ฆ‰, ํ•˜๋‚˜์˜ ๋„คํ”„๋ก ์€ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๊ธฐ๋Šฅ์„ ์ˆ˜ํ–‰: ์—ฌ๊ณผ(filtration), ํก์ˆ˜(resorption), ๋‚ด๋ถ„๋น„(endocrine).
    • ๋‚ด๋ถ„๋น„ ๊ธฐ๋Šฅ์—๋Š” ๋Œ€ํ‘œ์ ์œผ๋กœ renin-angiotensin-aldosterone์ด ์žˆ๋‹ค.
    • ์†Œ๋ณ€ ๋†๋„ ์กฐ์ ˆ
    • ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์—ญํ• ์€ ์ „ํ•ด์งˆ ํ‰ํ˜•์„ ๋งž์ถ”๋Š” ๊ฒƒ!


์‚ฌ๊ตฌ์ฒด์˜ ๊ธฐ๋ณธ ๊ตฌ์กฐ. ์ •์ƒ ๊ตฌ์กฐ๋ฅผ ์ž˜ ์•Œ๊ณ  ์žˆ์–ด์•ผ, ์—ผ์ฆ๊ณผ ๊ฐ™์€ ๋น„์ •์ƒ ์ƒํ™ฉ์„ ์ดํ•ดํ•  ์ˆ˜ ์žˆ๋‹ค! ์ž˜ ๊ธฐ์–ตํ•ด๋‘๊ธฐ.

  • Functions
    • ๋ฌผ๊ณผ ์ „ํ•ด์งˆ์˜ ๋†๋„ ์กฐ์ ˆ
    • ๋ถˆํ•„์š”ํ•œ ๋Œ€์‚ฌ์ฒด ๋ฐฐ์ถœ (์—ฌ๊ณผ = ํ•„์š”ํ•œ ๊ฑด ๋†”๋‘๊ณ , ํ•„์š”์—†๋Š” ๊ฑด ๋ฒ„๋ฆฐ๋‹ค!)
    • ํ˜ˆ์•• ์กฐ์ ˆ : Renin-angiotensin system์„ ํ†ตํ•ด
  • ๊ตฌ์„ฑ : kidneys - ureters - urinary bladder - urethra


์ „์‹  ์ˆœํ™˜์„ ํ•œ ํ˜ˆ์•ก์ด ์‹ ์žฅ์œผ๋กœ ๋“ค์–ด์˜ค๋Š”(afferent) ํ˜ˆ๊ด€ โ†’ ์‚ฌ๊ตฌ์ฒด โ†’ ์„ธ๋‡จ๊ด€์œผ๋กœ ์ด์–ด์ง€๋Š” ํ๋ฆ„์„ ์ž˜ ๋‚˜ํƒ€๋‚ธ ๊ทธ๋ฆผ.

Basic Nephron Structure
  • ์‹ ์žฅ ํ•˜๋‚˜์— ๋„คํ”„๋ก ์ด ๋ฐฑ๋งŒ ๊ฐœ ์ •๋„ ์กด์žฌ.
  • ๋„คํ”„๋ก ์ด 70% ์ด์ƒ ์ •์ƒ ๊ตฌ์กฐ์™€ ๋‹ฌ๋ผ์ ธ ๋ฒ„๋ฆฌ๋ฉด โ†’ fibrosis๋กœ ๋Œ€์ฒด๋˜๊ณ , irreversibleํ•˜๋‹ค.
  • ๋„คํ”„๋ก ์˜ ๊ตฌ์„ฑ ์š”์†Œ:
    • glomerulus โ†’ ์—ฌ๊ณผ(filtration)
    • Bowmanโ€™s capsule โ†’ collects filtrate
    • Proximal tubule โ†’ ์žฌํก์ˆ˜(reabsorption)
    • Loop of Henle โ†’ ๋‡จ์˜ ๋†์ถ•(urine concentration)
    • Distal tubule & collecting duct โ†’ ๋งˆ์ง€๋ง‰ ์žฌํก์ˆ˜์™€ ๋ฐฐ์ถœ (fine-tuning of sodium/water reabsorption)
  • Rich capilary network๋กœ ๋‘˜๋Ÿฌ์‹ธ์—ฌ ์žˆ๋‹ค. ์„ธ๋‡จ๊ด€ ์‚ฌ์ด์‚ฌ์ด์— ์กฐ๊ทธ๋งŒ ํ˜ˆ๊ด€๋“ค์ด ์กด์žฌํ•ด์„œ ์ง€์ง€, ์˜์–‘ ๊ณต๊ธ‰.
Juxtaglomerular Apparatus
  • Macula densa + Juxtaglomerular cells + Mesangial cells ์„ ํ•ฉ์ณ ์นญํ•˜๋Š” โ€˜์ง‘ํ•ฉ์ฒดโ€™.
  • ์ฃผ์š” ๊ธฐ๋Šฅ : ํ˜ˆ์••์„ ์กฐ์ ˆํ•˜๋Š” ๋‚ด๋ถ„๋น„
    • sodium concentration ์กฐ์ ˆ
      • ์‹ฌ์žฅ์—์„œ ๋“ค์–ด์˜ค๋Š” ํ˜ˆ๊ด€์—์„œ sodium์˜ ๋†๋„๋‚˜ ํ˜ˆ์•• ๋“ฑ์„ ๊ฐ์ง€(๋ชจ๋‹ˆํ„ฐ๋ง) โ†’ ํ•„์š”์— ๋”ฐ๋ผ ์ „ํ•ด์งˆ ์žฌํก์ˆ˜ ์ด‰์ง„or์–ต์ œ, ์ˆ˜๋ถ„ ์žฌํก์ˆ˜ ์ด‰์ง„or์–ต์ œํ•ด์„œ ๋†๋„๋ฅผ ์กฐ์ ˆํ•œ๋‹ค.
    • renin ๋ถ„๋น„ โ†’ RAAS system ํ™œ์„ฑํ™”์‹œํ‚ค๋Š” ์ฒซ๋ฒˆ์งธ ๊ธฐ๊ด€
    • ํ˜ˆ์•• ์กฐ์ ˆ ๊ธฐ๋Šฅ์ด ํ•ญ์ƒ ๋™๋ฐ˜๋œ๋‹ค. (์ „ํ•ด์งˆ์€ ํ•ญ์ƒ ๋ฌผ๊ณผ ๊ฐ™์ด ์›€์ง์ด๊ธฐ ๋•Œ๋ฌธ)
    • ์‚ฌ๊ตฌ์ฒด์—ฌ๊ณผ์œจ(GFR, glomerular filtration rate) ์†๋„ ์กฐ์ ˆ โ†’ ์š”๋กœ ๋ฐฐ์ถœํ•˜๋Š” ์†๋„๋ฅผ ๋†’์ด๊ฑฐ๋‚˜ ๋Šฆ์ถค โ†’ ์ฒด์•ก๋Ÿ‰ ์กฐ์ ˆ
  • ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธฐ๋ฉด ์ด๋Ÿฐ ๊ธฐ๋Šฅ์ด ๋ฌด๋„ˆ์งˆ ์ˆ˜ ์žˆ๋‹ค~ (ํ•˜์ง€๋งŒ ์—ฌ๊ธฐ์— ์—ผ์ฆ์ด ์ƒ๊ธฐ๋Š” ๊ฑด ๋ณ„๋กœ ๋ณด์ง€ ๋ชปํ–ˆ๋‹ค)
Mechanisms of Urine Formation

์˜ค์คŒ ํ˜•์„ฑ์˜ ์ฃผ์š” 3๊ฐ€์ง€ ๊ณผ์ •!

  • (1) ์—ฌ๊ณผ (Glomerular filtration)
  • (2) ์žฌํก์ˆ˜ (Tubular reabsorption)
  • (3) ๋ถ„๋น„ (Tubular secretion)

โ‡’ ์˜ค์คŒ์˜ ์ตœ์ข… ๋†๋„๋Š” ADH, aldosterone ๋“ฑ ํ˜ธ๋ฅด๋ชฌ ์‹ ํ˜ธ์— ์˜ํ•ด ๊ฐ•ํ•˜๊ฒŒ ์กฐ์ ˆ๋œ๋‹ค.

2. Glomerular Diseases

Key Concepts

  • Glomerulonephritis (์‚ฌ๊ตฌ์ฒด์‹ ์—ผ) : ๋ณดํ†ต ๋ฉด์—ญ๋งค๊ฐœ์„ฑ์ด๋‹ค.
    • (1) ์ „์‹ ์— immune complex(Ab-Ag) โ†‘ : ์ „์‹  ์งˆํ™˜์— ์˜ํ•œ ๋ฉด์—ญ๋งค๊ฐœ์„ฑ
    • (2) anti-GBM(GBM ์ž๊ฐ€ํ•ญ์ฒด) โ†‘ : ์ž๊ฐ€๋ฉด์—ญ์„ฑ
  • ์กฐ์งํ•™์ ์œผ๋กœ MPGN(mesangial cell์ด ๊ณผ์ฆ์‹) / Glomerulosclerosis(๋งŒ์„ฑ)
  • Nephrotic syndrome mechanisms

1) ์‚ฌ๊ตฌ์ฒด ์งˆํ™˜์˜ pathogenesis

  • ์‚ฌ๊ตฌ์ฒด๋Š” ์—ฌ๊ณผ๋ฅผ ๋‹ด๋‹น โ†’ ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธฐ๋ฉด ๋‚ด๋ณด๋‚ด์ง€ ๋ง์•„์•ผ ํ•  ๊ฒƒ๋“ค(๋ชธ์— ๊ฐ€์ง€๊ณ  ์žˆ์–ด์•ผ ํ•  ๊ฒƒ๋“ค)์ด ์†Œ์‹ค๋œ๋‹ค.
  • ์š”๊ฒ€์‚ฌ์ƒ ๋‹จ๋ฐฑ์งˆ์ด ๋งŽ์œผ๋ฉด proteinuria, RBC๊ฐ€ ๋งŽ์œผ๋ฉด hematuria
  • BUN, creatinine์ด ๋†’์•„์ง€๋ฉด uremia
  • ๋Œ€๋ถ€๋ถ„ ๋ฉด์—ญ๋งค๊ฐœ์„ฑ์ด๋‹ค (circulating immune complexes or autoantibodies)


Immune-Complex Glomerulonephritis. immunofluorescence์— ์˜ํ•ด immunoglobulin ์นจ์ฐฉ์ด ํ™•์ธ๋˜์—ˆ๋‹ค.

  • Type โ…ข hypersensitivity์— ์˜ํ•œ ๊ฒƒ์ด ๊ฐ€์žฅ ํ”ํ•˜๋‹ค.
    • immune complex๊ฐ€ ์‚ฌ๊ตฌ์ฒด์— ์ถ•์  โ†’ ๋ฉด์—ญ ๋ฐ˜์‘์— ์˜ํ•ด ๋ณด์ฒด ํ™œ์„ฑํ™” & ํ˜ธ์ค‘๊ตฌ ๋™์› โ†’ ์‚ฌ๊ตฌ์ฒด ์†์ƒ์œผ๋กœ ์ด์–ด์ง.
  • ๋œ ํ”ํ•˜๊ฒŒ๋Š” type โ…ก hypersensitivity์— ์˜ํ•ด์„œ ๋‚˜ํƒ€๋‚  ์ˆ˜๋„ ์žˆ๋‹ค. (anti-GBM antibodies์˜ ๊ฒฝ์šฐ)
  • โ‡’ ์‹ ์žฅ ํˆฌ๊ณผ์„ฑ์ด ์ฆ๊ฐ€ํ•˜๊ณ , ์ง€์†๋˜๋ฉด ๊ฒฐ๊ตญ glomerulosclerosis๋กœ ์ด์–ด์ง„๋‹ค.

2) Classfication of GN(Glomerulonephritis)

์กฐ์งํ•™์ ์œผ๋กœ ์•„๋ž˜์™€ ๊ฐ™์ด ๋ถ„๋ฅ˜ํ•  ์ˆ˜ ์žˆ๋‹ค. MPGN์ด๋ผ ํ•˜๋ฉด (mesangioproliferative๊ฐ€ ์•„๋‹ˆ๋ผ) ๋ง‰๊ณผ ์„ธํฌ ๋ชจ๋‘๊ฐ€ ์ฆ์‹ํ•˜๋Š” membranoproliferative GN์„ ์นญํ•œ๋‹ค.

์šฉ์–ด์•ฝ์–ด์ฃผ ๋ณ‘๋ณ€ ์œ„์น˜์ •์˜ ๋ฐ ํŠน์ง•
Membranous GNMGNGBM / capillary walldiffuse thickening of GBM
(๋ชจ์„ธํ˜ˆ๊ด€๋ฒฝ ๋น„ํ›„, ์„ธํฌ ์ฆ์‹์€ ์ ๋‹ค)
Mesangioproliferative GNMsPGNmesangiumexpansion of mesangial matrix and cells
Membranoproliferative GNMPGNCapillary wall + mesangiumGBM thickening + mesangial proliferation
Focal Segmental GlomerulosclerosisFSGSsegmental scarring of glomeruli


(์™ผ) Membranous GN, hyaline thickening์— ์˜ํ•ด membrane์ด ๋‘๊บผ์›Œ์กŒ๋‹ค. (์˜ค) Membranoproliferative GN, membrane๋„ ๋‘๊บผ์›Œ์กŒ์ง€๋งŒ ์„ธํฌ(mesangial cells)๊ฐ€ ํ›จ์”ฌ ์ฆ์‹ํ–ˆ๋‹ค.

โ˜‘๏ธ Other Classifications
  • Focal v. diffuse
  • Segmental vs. global
  • Acute vs.chronic

3) ์‚ฌ๊ตฌ์ฒด ๋ณ‘์ฆ์˜ ์ž„์ƒ์  ๊ฒฐ๊ณผ

  • Proteinuria : ์ž„์ƒ์ ์œผ๋กœ ์ค‘์š”์„ฑ์ด ํฌ๋‹ค. ์‚ฌ๊ตฌ์ฒด์˜ ์—ฌ๊ณผ ๊ธฐ๋Šฅ ์ƒ์‹ค์„ ์˜๋ฏธ.
    • ์‹ ์žฅ ์†์ƒ์„ ๋‚˜ํƒ€๋‚ด๋Š” ์ง€ํ‘œ์ธ ๋™์‹œ์—, ์‹ ์žฅ ์ƒํƒœ๋ฅผ ๊ณ„์† ์•…ํ™”์‹œํ‚จ๋‹ค.
  • Nephrotic syndrome : ์•„๋ž˜ 4๊ฐ€์ง€ ์ฆ์ƒ์ด ๋™๋ฐ˜๋˜์–ด ๊ด€์ฐฐ๋  ๋•Œ.
    • Marked proteinuria
    • Hypoalbuminemia (๋ฐ–์œผ๋กœ ๋งŽ์ด ๋ฐฐ์ถœ๋จ)
    • Edema (๊ทธ๋ž˜์„œ ๋ถ€์ข… - ์ •์ˆ˜์•• โ†“ & sodium retention โ†‘)
    • Hyperlipidemia
    • ( =๋ฐฐ์ถœ์ด ์ œ๋Œ€๋กœ ์ž‘๋™ํ•˜์ง€ ์•Š์•„์„œ ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ๋“ค!)
  • Hypercoagulability (๊ณผ์‘๊ณ  ๋˜ํ•œ ์‘๊ณ ์žฅ์• ๋‹ค!)
    • (๊ฐ„๋ฟ๋งŒ ์•„๋‹ˆ๋ผ) ์‹ ์žฅ ๋ฌธ์ œ์— ์˜ํ•ด์„œ๋„ ์‘๊ณ ์žฅ์• ๊ฐ€ ์ƒ๊ธด๋‹ค๋Š” ๊ฒƒ์„ ๊ธฐ์–ตํ•˜์ž.
    • ์‚ฌ๊ตฌ์ฒด ์—ฌ๊ณผ ๊ธฐ๋Šฅ ์ €ํ•˜ โ†’ antithrombin โ…ข ์œ ์ถœ ์ฆ๊ฐ€ โ†’ ๋ถˆํ•„์š”ํ•œ ํ˜ˆ์•ก ์‘๊ณ ๋ฅผ ๋ง‰์•„์ฃผ๋˜ antithrombin์ด ์†Œ์‹ค๋˜๋ฉด์„œ ๊ณผ๋„ํ•œ ํ˜ˆ์•ก ์‘๊ณ  ๋ฐœ์ƒ.

4) ๋งŒ์„ฑ - Glomerulosclerosis

  • ์‚ฌ๊ตฌ์ฒด ์†์ƒ์˜ ๋งŒ์„ฑ์  ๊ฒฐ๊ณผ.
  • fibrosis์— ์˜ํ•ด ๊ตฌ์กฐ์  ๋ณต๊ตฌ๋Š” ๊ฐ€๋Šฅํ•˜์ง€๋งŒ(collagen ์„ฑ๋ถ„์ด ์ฑ„์šด๋‹ค), ๊ธฐ๋Šฅ์  ๋ณต๊ตฌ๋Š” ๋ถˆ๊ฐ€๋Šฅํ•˜๋‹ค.
  • ๊ณ„์† ์ง„ํ–‰๋˜์–ด ์‚ฌ๊ตฌ์ฒด์˜ 3/4 ์ด์ƒ์ด ๋ง๊ฐ€์ง€๋ฉด chronic renal failure.


Glomerulosclerosis. ์ฝœ๋ผ๊ฒ ์„ฑ๋ถ„์ด ๊ฐ€๋“ ์ฑ„์›Œ ์‚ฌ๊ตฌ์ฒด ๊ตฌ์กฐ๋ฅผ ๊ฑฐ์˜ ํ™•์ธํ•˜๊ธฐ๋„ ์–ด๋ ต๋‹ค.

Role of Podocytes in Glomerular Injury

  • podocytes : ์ผ์ข…์˜ ์ƒํ”ผ์„ธํฌ, barrier intergrity๋ฅผ ์กฐ์ ˆํ•ด barrier์˜ ํ•ญ์ƒ์„ฑ์„ ์œ ์ง€ํ•œ๋‹ค.
  • podocyte๋Š” ์žฌ์ƒ์ด ์ž˜ ์•ˆ ๋œ๋‹ค. ๊ธฐ๋Šฅ์ • ํšŒ๋ณต์ด ์–ด๋ ค์›€.
  • ์น˜๋ฃŒ ๋˜ํ•œ ์ง„ํ–‰์„ ๋Šฆ์ถœ ๋ฟ,์™„์ „ํžˆ ์ •์ƒ ์ƒํƒœ๋กœ ๋Œ์•„๊ฐ€๊ธฐ๋Š” ์–ด๋ ต๋‹ค.
  • sclerosis๊ฐ€ ์ผ๋ถ€์—๋งŒ ๋จธ๋ฌผ๋Ÿฌ ์žˆ์„ ๊ฑด์ง€, ์ „์ฒด์ ์œผ๋กœ ์ƒ๊ธธ ๊ฑด์ง€ ๊ฒฐ์ •ํ•˜๋Š” ๋ฐ ์ค‘์š”ํ•˜๋‹ค.

์—ฌ๊ธฐ๊นŒ์ง€ Summary!

  • Glomerular injury โ†’ protein leakage โ†’ tubulointerstitial damage โ†’ fibrosis
  • Proteinuria is both a marker and driver of progression
  • Chronic GN leads to global glomerulosclerosis and ultimately end stage kidney
    • ์ด์ฏค ์ง„ํ–‰๋˜๋ฉด ๋ณต๊ตฌํ•  ์ˆ˜ ์—†๋Š” ์ƒํƒœ (ํˆฌ์„ ๋ฐ–์—๋Š” ๋ฐฉ๋ฒ•์ด ์—†๋‹ค.)
    • BUN, Creatinine ๋†๋„๋กœ ํ™•์ธ ๊ฐ€๋Šฅํ•˜๋ฉฐ ์š”๊ฒ€์‚ฌ์ƒ์˜ ๊ฒฐ๊ณผ๋Š” โ€˜azotemiaโ€™๋ผ๊ณ  ํ•œ๋‹ค. ์กฐ์งํ•™์  ์†Œ๊ฒฌ๊ณผ ์ƒ๊ด€๊ด€๊ณ„๋Š” ์žˆ์ง€๋งŒ ๋ฐ˜๋“œ์‹œ 1:1 ๋งค์นญ๋˜๋Š” ๊ฐœ๋…์€ ์•„๋‹ˆ๋‹ค. (ํ˜ˆ์ค‘ BUN, creatinine ๋†๋„๋ฅผ ๋ณด๊ณ ๋Š” โ€˜azotemiaโ€™, ์กฐ์งํ•™์  ์†Œ๊ฒฌ ์ƒ์˜ ํ‘œํ˜„์€ โ€˜end stage kidneyโ€™)
    • 3/4 ์ด์ƒ์ด ๋ง๊ฐ€์ง€๋ฉด โ€˜end-stageโ€™๋ผ๊ณ  ํ•œ๋‹ค.
  • Early diagnosis and management can slow the disease, but are often challenging in animals : ์ง„ํ–‰์„ ๋Šฆ์ถœ ์ˆ˜๋Š” ์žˆ์œผ๋‚˜, 1์ฐจ์  ์›์ธ์„ ์ฐพ์ง€ ๋ชปํ•˜๊ฑฐ๋‚˜ ์ „์‹ ์„ฑ ๋ฌธ์ œ์ผ ๊ฒฝ์šฐ ๊ด€๋ฆฌ๊ฐ€ ์–ด๋ ค์›Œ์ง„๋‹ค.

5) Glomerular Amyloidosis

(260526 ๋ณ‘๋ฆฌ ๋‹ค์‹œ)

3. Tubular and Interstitial Disorders

tubule๊ณผ ๊ทธ ์ฃผ๋ณ€์˜ ๊ฐ„์งˆ์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ์งˆ๋ณ‘์— ๋Œ€ํ•ด ์‚ดํŽด๋ณด์ž.

Key Concepts

  • Acute tubular injury : ๊ธ‰์„ฑ ์†์ƒ์˜ ์›์ธ์€ ischemia or toxin์œผ๋กœ ๊ตฌ๋ถ„ํ•  ์ˆ˜ ์žˆ๋‹ค.
    • Ischemia : ์‹ ์žฅ ์ž์ฒด์˜ ๋ฌธ์ œ๊ฐ€ ์•„๋‹ˆ๋ผ ์ „์‹ ์  ๋ฌธ์ œ์ผ ์ˆ˜๋„. ํ˜ˆ์••์ด ๋‚ฎ๊ฑฐ๋‚˜, ์ „์‹  ์ˆœํ™˜์ด ์•ˆ ๋˜๊ฑฐ๋‚˜ ํ•˜๋Š” ์ด์œ ๋กœ ๋“ค์–ด์˜ค๋Š” ํ˜ˆ์•ก๋Ÿ‰ โ†“
    • Toxin : ์‹ ์žฅ ๊ตฌ์กฐ ์ž์ฒด์— ์†์ƒ์„ ์ค€๋‹ค.
  • ์–ด๋А ์ •๋„์˜ ์†์ƒ์€ ๊ทน๋ณตํ•  ์ˆ˜ ์žˆ๋Š” ์žฅ๊ธฐํŠน์ด์ ์ธ ์ค„๊ธฐ์„ธํฌ๊ฐ€ ์žˆ๋‹ค.
  • Tubulointerstitial nephritis (์„ธ๊ด€์˜ ์†์ƒ๊ณผ ํ•จ๊ป˜ ์„ธ๊ด€ ์ฃผ๋ณ€์˜ ๊ฐ„์งˆ์—๋„ ์—ผ์ฆ์„ธํฌ๊ฐ€ ์นจ์œค)
    • ์›์ธ : ํฌ๊ฒŒ ๊ฐ์—ผ์„ฑ ์›์ธ์ฒด or ๋ฉด์—ญ๋งค๊ฐœ์„ฑ
    • ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ fibrosis๊ฐ€ ์ƒ๊ธฐ๊ณ  ๋งŒ์„ฑ์œผ๋กœ ์ง„ํ–‰๋  ์ˆ˜ ์žˆ๋‹ค. (๋Œ์ดํ‚ฌ ์ˆ˜ ์—†๋‹ค)
  • Viral nephritis : ๊ฐ์—ผ์„ฑ ์›์ธ์ฒด ์ค‘ ๋ฐ”์ด๋Ÿฌ์Šค์— ์˜ํ•œ ๊ฒƒ๋“ค์ด ๋งŽ๋‹ค.
  • Leptospiral nephritis : ์„ธ๊ท ์„ฑ ์›์ธ์ฒด ์ค‘ Leptospira์— ์˜ํ•œ ์‹ ์žฅ ์—ผ์ฆ์ด ํ”ํ•˜๋‹ค.

TIN์ด ๋งŽ์€๋ฐ, ์„ธ๋‡จ๊ด€์„ ๋จผ์ € ์†์ƒ์‹œํ‚ค๋Š” ์›์ธ์ฒด์ธ์ง€ ์—ผ์ฆ์„ ๊ฐ„์งˆ์— ์œ ๋ฐœํ•˜๋Š” ์›์ธ์ฒด์ธ์ง€ ์ค‘์š”

1) Acute Tubular Injury (ATI)

  • ์–ด๋–ค ์›์ธ์— ์˜ํ•ด ๊ธ‰์†๋„๋กœ ์„ธ๋‡จ๊ด€์ด ์†์ƒ๋œ ๊ฒƒ.
  • Acute renal failure (ARF) ๋ฅผ ์œ ๋ฐœํ•˜๋Š” ํ”ํ•œ ์›์ธ์ด๋‹ค. (*โ€˜failureโ€™๋ผ๋Š” ํ‘œํ˜„์€ 75% ์ด์ƒ ์†์ƒ๋  ๋•Œ ์“ด๋‹ค)
  • ์„ธ๋‡จ๊ด€์„ ํ˜•์„ฑํ•˜๋Š” ์ƒํ”ผ์„ธํฌ(tubular epithelial cells)๋“ค์€ ๋Œ€์‚ฌ์ ์œผ๋กœ ํ™œ์„ฑํ™”๋˜์–ด(highly metabolically active) ์žˆ์–ด ๊ธ‰์„ฑ ์†์ƒ์— ์ทจ์•ฝํ•˜๋‹ค.
    : ๋…์„ฑ ๋ฌผ์งˆ์˜ ๋Œ€์‚ฌ์ฒด๊ฐ€ ๋นจ๋ฆฌ ๋งŒ๋“ค์–ด์ง€๊ณ , ๊ทธ์— ์˜ํ•œ ์†์ƒ์ด๋‚˜ ๊ดด์‚ฌ๋„ ๋น ๋ฅด๊ฒŒ ์ง„ํ–‰.
  • (1์ฐจ์  ์›์ธ์ด ์ œ๊ฑฐ๋˜๊ณ ) Basement membrane์ด ์†์ƒ๋˜์ง€ ์•Š์•˜์œผ๋ฉด ์žฌ์ƒ์ด ๊ฐ€๋Šฅํ•˜๋‹ค.
1๏ธโƒฃ Ischemic Tubular Injury

๋จผ์ € ํ—ˆํ˜ˆ์„ฑ ์›์ธ์— ์˜ํ•œ ์‹ ์„ธ๋‡จ๊ด€์˜ ์†์ƒ์„ ์‚ดํŽด๋ณด์ž.

  • ์ฒด์•ก๋Ÿ‰์ด ์ค„์—ˆ์„ ๋•Œ ์†์ƒ์ด ์ผ์–ด๋‚  ์ˆ˜ ์žˆ๋‹ค.
    • Hypotension (์ฒด์•ก์ด ๋ถ€์กฑํ•ด์„œ ์ €ํ˜ˆ์••)
    • (hypovolemic) shock (์•„์ฃผ ์‹ฌํ•œ ์ถœํ˜ˆ ๋“ฑ์— ์˜ํ•ด ์ฒด์•ก๋Ÿ‰์ด ์ค„์—ˆ์„ ๋•Œ)
    • severe dehydration (์•„์ฃผ ์‹ฌํ•œ ํƒˆ์ˆ˜)
  • Patch(๊ทœ์น™ ์—†์ด ๋‹ค๋ฐœ์„ฑ) necrosis, ๊ทผ์œ„์„ธ๋‡จ๊ด€,

  • ์„ธ๋‡จ๊ด€ ์†์ƒ โ†’ ์„ธ๋‡จ๊ด€ ๋‚ด๊ฐ•์œผ๋กœ cell debris ๋–จ์–ด์ง โ†’ ์ด debris๋“ค์ด ๊ฑฐ์Šฌ๋Ÿฌ ์˜ฌ๋ผ๊ฐ€์„œ(back-leak) ๊ฑฐ๊พธ๋กœ ์‚ฌ๊ตฌ์ฒด์—ฌ๊ณผ์œจ์„ ๋–จ์–ด๋œจ๋ฆด ์ˆ˜ ์žˆ๋‹ค.
2๏ธโƒฃ Toxic Tubular Injury

์„ธ๋‡จ๊ด€์„ ์†์ƒ์‹œํ‚ฌ ์ˆ˜ ์žˆ๋Š” ๋…์„ฑ ๋ฌผ์งˆ์„ ์‚ดํŽด๋ณด์ž.

  • Nephrotoxins
    • Plants : lilies(cat) ๋“ฑ (์šฐ๋ฆฌ๋‚˜๋ผ๋Š” ํ™˜๊ฒฝ์ ์œผ๋กœ ์‹๋ฌผ์„ฑ ๋…์†Œ์— ๋…ธ์ถœ์ด ์ ์€ ํŽธ)
    • Drugs : aminoglycosides, NSAIDs
    • Heavy metals : lead, mercury
    • Endogenous toxins : myoglobin, hemoglobin (๋Œ€์‚ฌ๋œ ํ˜•ํƒœ๋Š” ๋…์„ฑ์„ ๋ ์ง€ ์•Š์ง€๋งŒ, ๊ณผ๋„ํ•˜๊ฒŒ ๋งŽ์•„์„œ ์—ฌ๊ณผ๋˜์ง€ ๋ชปํ•˜๊ณ  ์„ธ๋‡จ๊ด€์— ๊ทธ๋Œ€๋กœ ๋„๋‹ฌํ•˜๋ฉด ๋…์„ฑ)
  • ๋…์„ฑ ๋ฌผ์งˆ์— ์˜ํ•œ necrosis๋Š” diffuse pattern์„ ๋‚˜ํƒ€๋‚ธ๋‹ค. (๊ฑฐ์˜ ํ˜ˆํ–‰์„ฑ์ด์–ด์„œ ์ „์ฒด์ ์œผ๋กœ ์†์ƒ)
โœด๏ธ Regeneration and Recovery

์žฅ๊ธฐํŠน์ด์ ์ธ ์ค„๊ธฐ์„ธํฌ๊ฐ€ ์กด์žฌํ•˜๋Š”์ง€, basemembrane์ด ๋ฉ€์ฉกํ•œ์ง€, ์†์ƒ ๋ฒ”์œ„๊ฐ€ ์ข์€์ง€ ๋“ฑ์ด ์žฌ์ƒ ์—ฌ๋ถ€๋ฅผ ๊ฒฐ์ •ํ•œ๋‹ค.

  • ์ •์ƒ ์„ธํ‘œ๊ด€ ์ƒํ”ผ์„ธํฌ : apex ์ชฝ(๋‚ด๊ฐ• ์ชฝ)์— brush border๋ฅผ ๊ฐ€์ง€๊ณ , ๊ฐ€์šด๋ฐ ํ˜น์€ ๋ฐ”๋‹ฅ ์ชฝ์— ํ•ต์„ ๊ฐ€์ง„๋‹ค(=๊ทน์„ฑ).
  • ์ฃฝ์–ด๊ฐ€๋Š”/์ฃฝ์€ ์„ธํฌ์˜ ํŠน์ง• : (1) polarity๋ฅผ ์žƒ๋Š”๋‹ค. and/or (2) brush border๋ฅผ ์žƒ๋Š”๋‹ค.

์†์ƒ ํ›„ ์žฌ์ƒ ๊ณผ์ •


์„ธ๋‡จ๊ด€ ์ƒํ”ผ์„ธํฌ์˜ regeneration & recovery ๊ณผ์ •.

  1. resolve stem cells(ํ‰์†Œ์—๋Š” ๊ธฐ๋Šฅํ•˜์ง€ ์•Š์ง€๋งŒ ์†์ƒ ๋ฐœ์ƒ ์‹œ ์ฆ์‹ํ•˜๊ณ  ๋ถ„ํ™”)์— ์˜ํ•ด ์†์ƒ๋œ ๋ถ€๋ถ„์ด ๋Œ€์ฒด๋œ๋‹ค.
  2. ์†์ƒ๋œ ์„ธํฌ๋“ค์€ ๋‚ด๊ฐ• ์ชฝ์œผ๋กœ ๋–จ์–ด์ ธ ๋‚˜์˜จ๋‹ค.
  3. ์„ธ๋‡จ๊ด€์€ ๊ณ„์† flow๊ฐ€ ํ๋ฅด๊ธฐ ๋•Œ๋ฌธ์— debris๋Š” ์”ป๊ฒจ ๋‚˜๊ฐ€๊ณ , ์ƒˆ๋กœ ๋งŒ๋“ค์–ด์ง„ ์„ธํฌ๊ฐ€ ์ž๋ฆฌ๋ฅผ ์ฑ„์šด๋‹ค. (๊ตฌ์กฐ์  ํšŒ๋ณต)
  4. ์‹ค์งˆ์  ํšŒ๋ณต์€ ์„ธํฌ์˜ polarity์™€ brush border๊นŒ์ง€ ํšŒ๋ณต๋˜์–ด์•ผ ์™„๋ฃŒ๋œ๋‹ค.

* ์žฌ์ƒ์„ ์œ„ํ•ด์„œ๋Š” basement membrane์ด ๋ฐ˜๋“œ์‹œ intactํ•ด์•ผ ํ•œ๋‹ค. * ์†์ƒ ํ›„ ํšŒ๋ณต๊นŒ์ง€ ์ˆ˜ ์ผ ๋˜๋Š” ์ˆ˜ ์ฃผ๊ฐ€ ๊ฑธ๋ฆด ์ˆ˜ ์žˆ๋‹ค.

2) Tubulointestitial Nephritis (TIN, ๊ฐ„์งˆ์„ฑ ์‹ ์—ผ)

  • ์—ผ์ฆ์ด ์„ธ๋‡จ๊ด€๊ณผ ๊ฐ„์งˆ์— ๋™์›๋˜๋Š” ํ˜•ํƒœ.
  • ๊ฐ์—ผ์„ฑ ์›์ธ์ฒด, ๋…์„ฑ ๋ฌผ์งˆ, ๋ฉด์—ญ๋งค๊ฐœ์„ฑ ๋“ฑ์œผ๋กœ ์ธํ•ด ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ๋‹ค.

โญ๏ธ โ€œTubulointerstitialโ€ ๋กœ ๋ฌถ์–ด์„œ ์–˜๊ธฐํ•˜๋Š” ์ด์œ 

  • ์ฒ˜์Œ์—๋Š” ์„ธ๋‡จ๊ด€์— ๋ฌธ์ œ๊ฐ€ ์ƒ๊ธด๋‹ค. (๋…์„ฑ ๋ฌผ์งˆ์ด๋“ , ๊ฐ์—ผ์„ฑ ์›์ธ์ฒด๋“ )
    1. ์„ธ๋‡จ๊ด€ ์ƒํ”ผ์„ธํฌ์˜ ๊ดด์‚ฌ
    2. ๊ดด์‚ฌ๋œ ์„ธํฌ๋Š” ์—ผ์ฆ ๋ฐ˜์‘์„ ์œ ๋ฐœํ•˜๋ฏ€๋กœ(DAMPs), ์—ผ์ฆ์„ธํฌ๊ฐ€ ๋™์›๋œ๋‹ค.
    3. ์„ธ๋‡จ๊ด€ ์ฃผ๋ณ€์˜ ์‚ฌ์ด์‚ฌ์ด ๋ชจ์„ธํ˜ˆ๊ด€์„ ํƒ€๊ณ  ์—ผ์ฆ์„ธํฌ๊ฐ€ ์นจ์œค
    4. ๊ฐ„์งˆ์— ์—ผ์ฆ์ด ๋ฐœ์ƒํ•œ๋‹ค.
  • ๋”ฐ๋ผ์„œ ๋งŽ์€ ๊ฒฝ์šฐ ์„ธ๋‡จ๊ด€ ์†์ƒ์€ tubulointerstitial nephritis๋ฅผ ์œ ๋ฐœํ•˜๋Š” ์›์ธ์ด๋‹ค.

์ถ•์ข…๋ณ„ ์›์ธ์ฒด (๋ฐ˜๋“œ์‹œ ์™ธ์šฐ์„ธ์š”)

  • ๋ง์—์„œ๋Š” ๋ฐ”์ด๋Ÿฌ์Šค์„ฑ ์›์ธ์ฒด(equine viral arteritis),
  • ์†Œ์—์„œ๋Š” ์„ธ๊ท ์„ฑ ์›์ธ์ฒด(Escherichia coli, Leptospira interrogans) ๊ฐ€ ์ž˜ ์•Œ๋ ค์ ธ ์žˆ๋‹ค.
  • ๊ฐœ์˜ ๊ฒฝ์šฐ ๊ฐ„์งˆ์„ฑ ์‹ ์—ผ์„ ์ผ์œผํ‚ค๋Š” ์›์ธ์ฒด๋“ค์ด โ†‘

์กฐ์งํ•™์ ์œผ๋กœ ๊ตฌ๋ถ„ํ•ด๋ณด์ž๋ฉด,

  • Acute TIN โ†’ edema, neutrophils, necrosis (๊ธ‰์„ฑ ์—ผ์ฆ์˜ ํŠน์ง•)
  • Chronic TIN โ†’ fibrosis, ๋‹จํ•ต๊ตฌ ๊ณ„ํ†ต ์นจ์œค(lymphocytes ๋“ฑ), ์žฌ์ƒ์ด ์•ˆ๋˜๊ณ  ์œ„์ถ•๋จ(tubular atrophy)


๋งŒ์„ฑ ๊ฐ„์งˆ์„ฑ ์‹ ์—ผ์˜ ์œก์•ˆ์ , ์กฐ์งํ•™์  ์†Œ๊ฒฌ. ์„ฌ์œ ํ™”๊ฐ€ ์ง„ํ–‰๋˜๋ฉด ํ‘œ๋ฉด์ด ์šธํ‰๋ถˆํ‰ํ•ด์ง€๊ณ  ์œ„์ถ•๋œ๋‹ค. ๋˜ํ•œ ๊ฐ„์งˆ ๋ถ€๋ถ„์— plasma cell, lymphocytes, macrophages ๋“ฑ ์—ผ์ฆ์„ธํฌ๋“ค์ด ์นจ์œค๋˜์–ด ๊ต‰์žฅํžˆ ํ™•์žฅ๋œ๋‹ค.

(C๋ฅผ ๋ณด๋ฉด ์‚ฌ๊ตฌ์ฒด๋Š” ๋น„๊ต์  ๋ฉ€์ฉกํ•œ ํŽธ์ด๋‹ค: ์‚ฌ๊ตฌ์ฒด ์›์ธ๊ณผ ์„ธ๋‡จ๊ด€ ์›์ธ์€ ๋น„๊ต์  ๋ณ‘๋ณ€์ด ๋…๋ฆฝ์ ์œผ๋กœ ๋‚˜ํƒ€๋‚œ๋‹ค. ๊ฐœ๋ณ„์ ์œผ๋กœ ์ง„ํ–‰๋˜๋‹ค๊ฐ€ ํ•ฉ์ณ์ง„๋‹ค. ํ˜„์žฌ๋Š” ์„ธ๋‡จ๊ด€ ์ชฝ์—๋งŒ ๋ณ‘๋ณ€์ด ์žˆ์Œ. Glomerulonephritis์™€ Tubulointerstitial nephritis๋ฅผ ๋”ฐ๋กœ ๊ตฌ๋ถ„ํ•˜๋Š” ์ด์œ !)

1๏ธโƒฃ (๋Œ€ํ‘œ์ ์ธ ์›์ธ์ฒด) Leptospiral Nephritis
  • Leptospira interrogans ์— ์˜ํ•ด ์œ ๋ฐœ : ๊ฐœ, ๋ผ์ง€, ์†Œ ๋ชจ๋‘์—์„œ ๋ณ‘๋ณ€์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค. (์ข…๊ฐ„ ๊ต์ฐจ๊ฐ์—ผ ๊ฐ€๋Šฅ!)

  • Acute(์ดˆ๊ธฐ) :
    • ์ถœํ˜ˆ ๋ถ€์œ„ ์กด์žฌ (์ง„ํ•œ ํ˜ธ์‚ฐ์„ฑ)
    • (์ •์ƒ ์„ธ๋‡จ๊ด€์ด๋ผ๋ฉด ๋™๊ทธ๋ž€ ํ˜ธ์—ผ์„ฑ ํ•ต๋“ค์ด ๋‚˜๋ž€ํžˆ ๋Š˜์–ด์„œ ์žˆ์–ด์•ผ ํ•˜๋Š”๋ฐ,) ํ•ต์ด ๋“ฌ์„ฑ๋“ฌ์„ฑ ์กด์žฌ (์„ธ๋‡จ๊ด€ ์†์ƒ์ž„์„ ์•Œ ์ˆ˜ ์žˆ๋‹ค)
    • ์—ผ์ฆ์„ธํฌ๊ฐ€ ๊ด€์ฐฐ๋˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ๋‹ค!! (ํ˜ˆ๊ด€ ์†์ƒ, ์„ธ๋‡จ๊ด€ ์†์ƒ์ด ์œ ๋ฐœ๋˜์—ˆ์ง€๋งŒ ์•„์ง ์—ผ์ฆ์„ธํฌ๊ฐ€ ๋„๋‹ฌํ•˜๊ธฐ ์ „์ผ ์ˆ˜ ์žˆ๋‹ค)
  • Leptospira๋Š” ๊ฐ„์—๋„ ๊ฐ์—ผ์ด ๋  ์ˆ˜ ์žˆ๋‹ค โ†’ ์ „์‹ ๊ฐ์—ผ์— ์˜ํ•œ or ์‹ ์žฅ ๋‹จ๋… ๊ฐ์—ผ์— ์˜ํ•œ leptospirosis?
    • ํ™ฉ๋‹ฌ์ด ๊ด€์ฐฐ๋˜๋ฉด ์ „์‹ ๊ฐ์—ผ ์˜์‹ฌ
  • ์ข…์ข… ๋ฌด์ฆ์ƒ์ธ ์ฑ„๋กœ(subclinical) ๋๋‚  ์ˆ˜๋„ ์žˆ์ง€๋งŒ, renal failure๊ฐ€ ๋ฐœ์ƒํ•  ๋งŒํผ ์‹ฌ๊ฐํ•œ ์ƒํƒœ๋กœ ์ง„ํ–‰๋  ์ˆ˜๋„ ์žˆ๋‹ค.
2๏ธโƒฃ (๋˜ ๋‹ค๋ฅธ ์›์ธ์ฒด) Viral Nephritis

๋ฐ”์ด๋Ÿฌ์Šค ๊ฐ์—ผ์— ์˜ํ•œ ๊ฐ„์งˆ์„ฑ ์‹ ์—ผ (์‹ ์„ธ๋‡จ๊ด€ ์†์ƒ)!

  • ๊ฐœ์—์„œ๋Š” Canine herpesvirus-1, ๋ผ์ง€์—์„œ๋Š” Porcine circovirus-2 ๊ฐ€ ๊ฐ„์งˆ์„ฑ ์‹ ์—ผ์„ ์œ ๋ฐœํ•˜๋Š” ์œ ๋ช…ํ•œ ์›์ธ์ฒด!
    • Canine herpesvirus-1 : renal necrosis์™€ hemorrhage๋ฅผ ์œ ๋ฐœํ•œ๋‹ค. (๋ฐ”์ด๋Ÿฌ์Šค๋“ค์€ ํ”ํžˆ ํ˜ˆ๊ด€์นœํ™”์„ฑ์„ ๊ฐ€์ ธ ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ๋ฅผ ์†์ƒ์‹œํ‚จ๋‹ค.)
  • Avian infectiious bronchitis๋„ ์‹ ์„ธ๋‡จ๊ด€์˜ ์ƒํ”ผ์„ธํฌ๋ฅผ ์†์ƒ์‹œํ‚ค๊ณ  2์ฐจ์ ์œผ๋กœ lymphcyte ์นจ์œค์„ ์ด‰์ง„ํ•œ๋‹ค.


Canine herpesvirus nephritis, neonatal puppy. ์‹ ์ƒ๊ฒฌ์—์„œ ๋น„๋‡จ ๋ฌธ์ œ, ์‹ ์žฅ์— ์ ์ƒ ์ถœํ˜ˆ โ†’ herpesvirus type โ… ์„ ์šฐ์„ ์ ์œผ๋กœ ๊ณ ๋ คํ•œ๋‹ค.

3๏ธโƒฃ Chronic Interstitial Nephritis

๊ฐ„์งˆ์„ฑ ์‹ ์—ผ์ด ๊ธ‰์„ฑ ๋‹จ๊ณ„์—์„œ ํ•ด๊ฒฐ๋˜์ง€ ์•Š๊ณ  ๋งŒ์„ฑ์œผ๋กœ ์ง„ํ–‰๋œ๋‹ค๋ฉด..

  • ์กฐ์งํ•™์  ํŠน์ง•
    • Interstitial fibrosis : ๊ฐ„์งˆ์˜ ์„ฌ์œ ํ™”๋Š” ๊ฐ€์žฅ ๋‘๋“œ๋Ÿฌ์ง€๋Š” ํŠน์ง•์ด๋‹ค.
    • Mononuclear cell infiltrates : ๊ฐ„์งˆ์— ๋‹จํ•ต๊ตฌ ๊ณ„์—ด(lymphocytes, plasma cell, ๋“œ๋ฌผ๊ฒŒ macrophages ๋“ฑ)์ด ๋งŽ์ด ์นจ์œคํ•œ๋‹ค. โ‡’ ์‚ฌ๊ตฌ์ฒด ์œ„์ถ•
    • Tubular atrophy and dilation :
  • primary lesion์ผ ์ˆ˜๋„ ์žˆ๊ณ , ์‚ฌ๊ตฌ์ฒด/์„ธ๋‡จ๊ด€ ์†์ƒ์— ๋”ฐ๋ผ 2์ฐจ์ ์œผ๋กœ ์˜ค๊ธฐ๋„ ํ•œ๋‹ค(๋”ํ”ํ•จ).

โœด๏ธ Tubular and Interstitial Lesions in End-Stage Kidney Disease
  • ๋งŒ์„ฑ์ ์œผ๋กœ ์ง„ํ–‰๋˜๋ฉด
    • ์œก์•ˆ์ ์œผ๋กœ๋Š” ์žฅ๊ธฐ๊ฐ€ ์œ„์ถ•๋˜๊ณ , ๊ด‘๋ฒ”์œ„ํ•œ ์„ฌ์œ ํ™” ๋•Œ๋ฌธ์— ํ‘œ๋ฉด์ด ์šธํ‰๋ถˆํ‰ํ•ด์ง„๋‹ค.
    • (๊ฐ„์ด ์ž‘์•„์ง€๋Š” ๊ฒฝ์šฐ๋Š” PSS / ํ›„์ฒœ์ ์ธ end-stage liver or cirrhosis๊ฐ€ ์žˆ์—ˆ๋‹ค โ‡’ ์‹ ์žฅ์—์„œ๋„ ๋™์ผ. ์‹ฌํ•œ fibrosis ๋กœ ์ธํ•ด ์šธํ‰๋ถˆํ‰ํ•ด์ง€๋ฉด์„œ ํฌ๊ธฐ๋Š” ์ž‘์•„์ง„๋‹ค.)

โœ”๏ธ Hallmarks of end-stage kidney (์•”๊ธฐ)

  • Widespread fibrosis
  • Tubular dropout
  • Regenerative nodules
  • Thickened arterioles


Chronic Interstitial Nephritis.

4. Vascular and Metabolic Diseases

Key Concepts

  • Renal infarcts (ํ—ˆํ˜ˆ์— ์˜ํ•œ ๋ถ€๋ถ„ ๊ดด์‚ฌ)
  • Hypertension-related changes (๊ณ ํ˜ˆ์•• ๊ด€๋ จ)
  • ์นผ์Š˜ ๋†๋„๊ฐ€ ๋†’์•„์กŒ์„๋•Œ - hypercalcemia-induced mineralization
  • Fibrous osteodystrophy โ† renal secondary hyperparathyroidism
  • Anemia (๋นˆํ˜ˆ์— ์˜ํ•œ ๋ณ€ํ™”๋“ค) and metabolic derangemenets
1๏ธโƒฃ Renal infarction & hemorrhage
  • End-arteries(๊ฐ€์žฅ ๋ง๋‹จ๋ถ€ ํ˜ˆ๊ด€)์ด ๋ง‰ํ˜”์„ ๋•Œ ๋ฐœ์ƒํ•œ๋‹ค.
    • ๋Œ€๋ถ€๋ถ„์˜ ์žฅ๊ธฐ๋Š” ํ˜ˆ์•ก์„ ๊ณต๊ธ‰ํ•˜๋Š” ํ˜ˆ๊ด€์ด ์—ฌ๋Ÿฌ ๊ฐœ ์žˆ๋Š”๋ฐ, ์‹ ์žฅ์˜ end-artery์˜ ๊ฒฝ์šฐ ์œ ์ผํ•˜๊ฒŒ ๊ทธ ํ˜ˆ๊ด€์œผ๋กœ๋งŒ ํ˜ˆ์•ก์ด ๊ณต๊ธ‰๋˜๋Š” ๊ฒƒ. (no collateral supply)
  • ํ์ƒ‰์˜ ์ฃผ์š” ์›์ธ: thromboembolism (ํ˜ˆ์ „์ด ๋‘ฅ๋‘ฅ ๋– ๋‹ค๋‹ˆ๋Š”๋ฐ, ์ž‘์€ ํ˜ˆ๊ด€์ด ์‰ฝ๊ฒŒ ๋ง‰ํž˜ โ†’ ๋ถ€๋ถ„์  ํ—ˆํ˜ˆ), vasculitis, septicemia (ํ˜ˆํ–‰์ด ์›ํ™œํ•˜์ง€ ์•Š์Œ)
  • ์ฒ˜์Œ์— ํ˜ˆ๊ด€ obstruction โ†’ ์ถœํ˜ˆ(wedge-shaped), ์ฒ˜์Œ์—๋Š” ๋ถ€ํ’€์–ด๋ณด์ž„ โ†’ ์„ฌ์œ ํ™”๋กœ ๋Œ€์ฒด๋˜๋ฉด์„œ ์ˆ˜์ถ•
  • โ‡’ pale wedges with hemorrhagic margins, ๋งŒ์„ฑํ™”๋˜๋ฉด fibrotic and distorted.


A, B - Acute renal infarcts. C -Chronic infarcts. swollen & hemorrhagic โ†’ pale โ†’ shrunken & fibrotic. ๋งŒ์„ฑ์œผ๋กœ ์ง„ํ–‰๋˜๋ฉด ์ฐฝ๋ฐฑํ•ด์ง€๊ณ  ์ˆ˜์ถ•ํ•œ๋‹ค.


Acute infarct, kidney, dog.

2๏ธโƒฃ Hypercalcemia-Induced Nephropathy

ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„๊ฐ€ ๋†’์•„์ ธ์„œ ๋‚˜ํƒ€๋‚˜๋Š” ๋ฌธ์ œ.

  • hypercalceima๋กœ ์‹ ์žฅ ๋ฌธ์ œ๊ฐ€ ๋ฐœ์ƒํ•  ์ˆ˜๋„ ์žˆ์ง€๋งŒ, ์‹ ์žฅ ๋ฌธ์ œ๋กœ hypercalcemia๊ฐ€ ์œ ๋ฐœ๋  ์ˆ˜๋„ ์žˆ๋‹ค.
  • ์›์ธ:
    • (1) Primary hyperparathyroidism (๋ถ€๊ฐ‘์ƒ์„  ๊ธฐ๋Šฅ ํ•ญ์ง„์ฆ) โ†’ ๋ผˆ์˜ ์žฌํก์ˆ˜๊ฐ€ ๋Š˜์–ด๋‚˜ ์นผ์Š˜ ๋†๋„ ์ฆ๊ฐ€
    • (2) Paraneoplastic syndrome โ†’ hyperparathyroidism๊ณผ ๊ฐ™์€ ํšจ๊ณผ
      • PTHrP-producing tumors : lymphoma, apocrine gland adenocarcinoma of the anal sac
    • (3) Vitamin D toxicosis
    • (4) Chronic Renal failure :
      • ๋งŒ์„ฑ ์‹ ๋ถ€์ „ โ†’ phosphate์˜ ๋ฐฐ์ถœ ๊ฐ์†Œ(ํ˜ˆ์ค‘ ๋†๋„ ์ฆ๊ฐ€) โ†’ ์นผ์Š˜๊ณผ ๊ฒฐํ•ฉํ•˜๋ ค๊ณ  ํ•จ (calcium phosphate) โ†’ ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„ ๊ฐ์†Œ โ†’ ๋ถ€๊ฐ‘์ƒ์ƒ˜์—์„œ PTH ๋ถ„๋น„ โ†’ Ca2+ ์ ‘ํ•ฉ์ฒด๊ฐ€ ๋” ๋Š˜์–ด๋‚จ โ†’ ํ™”ํ•ฉ๋ฌผ์ด ๋Œ์•„๋‹ค๋‹ˆ๋ฉด์„œ ์—ฐ๋ถ€์กฐ์ง(ํŠนํžˆ ์‹ ์žฅ; ์‹ ์„ธ๋‡จ๊ด€, ํ˜ˆ๊ด€๋ฒฝ)์— ์นจ์ฐฉ โ†’ ๊ธฐ๋Šฅ์ €ํ•˜ ์‹ฌํ™”
    • (5) Granulomatous disease (ex. ๊ณฐํŒก์ด ๊ฐ์—ผ โ†’ macrophage-mediated calcitriol โ†‘)
  • ๋งŒ์„ฑ์œผ๋กœ ์ด์–ด์ง€๋ฉด ์‹ฌํ•œ interstitial fibrosis, renal dysfunction์œผ๋กœ ์ด์–ด์ง„๋‹ค.


Nephrocalcinosis, dog. ๊ฐ„์งˆ, ๊ธฐ์ €๋ง‰, ์„ธ๋‡จ๊ด€ ๋“ฑ์— white streaks โ†’ ์นผ์Š˜์ด ์นจ์ฐฉ๋˜์–ด ์ƒ๊ธฐ๋Š” ์œก์•ˆ ์†Œ๊ฒฌ.

Hypercalcemia-induced nephropathy

A. Tubular Mineralization

  • In hypercalcemic states, calcium-phosphate complexes precipitate within tubular lumens and epithelial cells.
  • Especially prominent in the distal tubules and collecting ducts.
  • These deposits lead to tubular obstruction and epithelial cell necrosis.

(ํ˜ˆ์•ก ๋‚ด ๋งŽ์•„์ง„ ์นผ์Š˜ ์ด์˜จ๋“ค์ด ์ธ์‚ฐ๊ณผ ๊ฒฐํ•ฉํ•˜์—ฌ Ca-P ๋ณตํ•ฉ์ฒด ํ˜•์„ฑ โ†’ ์„ธ๋‡จ๊ด€ ๋‚ด๊ฐ•๊ณผ ์ƒํ”ผ์„ธํฌ (ํŠนํžˆ ์›์œ„์„ธ๋‡จ๊ด€๊ณผ ์ง‘ํ•ฉ๊ด€) ์— ์นจ์ฐฉ โ†’ ์„ธ๋‡จ๊ด€ ํ์‡„, ์ƒํ”ผ์„ธํฌ ๊ดด์‚ฌ)


B. Vasoconstriction

  • Hypercalcemia promotes afferent arteriole constriction, reducing renal blood flow.
  • This results in decreased GFR and potential ischemic injury.

(ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„๊ฐ€ ๋†’์•„์ง€๋ฉด ์‹ ์žฅ์œผ๋กœ ๋“ค์–ด์˜ค๋Š” afferent arteriole ์ˆ˜์ถ• โ†’ ์‹ ์žฅ ํ˜ˆ๋ฅ˜๋Ÿ‰ ๊ฐ์†Œ โ†’ GFR ๊ฐ์†Œ & ํ—ˆํ˜ˆ์„ฑ ์†์ƒ์˜ ์œ„ํ—˜โ†‘)


C. Nephrogenic Diabetes Insipidus

  • High calcium levels impair the action of antidiuretic hormone (ADH) on collecting ducts.
  • Leads to polyuria, dehydration, and reduced renal concentrating ability.

(์นผ์Š˜ ๋†๋„๊ฐ€ ๋†’์•„์ง€๋ฉด ์ง‘ํ•ฉ๊ด€์—์„œ ADH์˜ ์ž‘์šฉ์ด ๋–จ์–ด์ง โ†’ ๋ฌผ์„ ๊ทธ๋Œ€๋กœ ๋‚ด๋ณด๋‚ด๋‹ˆ ๋‹ค๋‡จ, ํƒˆ์ˆ˜, ์š”๋†์ถ• ๋Šฅ๋ ฅ ์ƒ์‹ค)


D. Interstitial Fibrosis (๊ฐ„์งˆ์„ฑ ์„ฌ์œ ํ™”)

  • Chronic injury initiates inflammation and fibrogenesis.
  • Eventually results in irreversible tubular atrophy and glomerular sclerosis.

(๋งŒ์„ฑ์ ์ธ ์†์ƒ์ด ์ง€์†๋˜๋ฉด ๋ชธ์€ ์—ผ์ฆ ๋ฐ˜์‘๊ณผ ์„ฌ์œ ํ™” ํ˜•์„ฑ โ†’ ๋น„๊ฐ€์—ญ์ ์ธ ์„ธ๋‡จ๊ด€ ์œ„์ถ•๊ณผ ์‚ฌ๊ตฌ์ฒด ๊ฒฝํ™”์ฆ์œผ๋กœ ์ด์–ด์ง)


โ‡’ Leads to fibrous osteodystrophy (especially in young animals) (์ง€์†๋œ ์†์ƒ์œผ๋กœ ๋น„ํƒ€๋ฏผD ํ™œ์„ฑํ™” โ†“ , ์ธ ๋ฐฐ์„ค โ†“ โ‡’ secondary hyperparathyroidism โ†’ ๋ผˆ์—์„œ ์นผ์Š˜์„ ๊ณ„์† ๋นผ๋‚ด๊ณ , ๋ผˆ๊ฐ€ ์„ฌ์œ ์กฐ์ง์œผ๋กœ ๋Œ€์ฒด๋จ)

3๏ธโƒฃ Anemia of CKD
  • ๋งŒ์„ฑ ์‹ ๋ถ€์ „๊ณผ ๋นˆํ˜ˆ์€ ์–ด๋–ค ์—ฐ๊ด€์„ฑ์ด ์žˆ์„๊นŒ?
  • ์‹ ์žฅ์—์„œ ๋ถ„๋น„๋˜๋Š” ๋ฌผ์งˆ ์ค‘ ์กฐํ˜ˆ์„ ์ด‰์ง„ํ•˜๋Š” EPO(erythropoietin)์ด๋ผ๋Š” ๋‹จ๋ฐฑ์งˆ๋„ ์žˆ๋‹ค. EPO๊ฐ€ ์ •์ƒ์ ์œผ๋กœ ๋ถ„๋น„๋˜์ง€ ์•Š๋‹ค ๋ณด๋‹ˆ ๋นˆํ˜ˆ์ด ์˜ค๊ฒŒ ๋œ๋‹ค.
  • ํ•œํŽธ์œผ๋กœ ์‹ ๋ถ€์ „์œผ๋กœ ์ธํ•œ ๋…์„ฑ ๋ฌผ์งˆ(uremic toxins)์ด RBC lifespan์„ ์งง๊ฒŒ ๋งŒ๋“œ๋Š” ๊ฒƒ๋„ ์ด์œ  ์ค‘ ํ•˜๋‚˜.
  • ๋นˆํ˜ˆ๊ณผ ๊ด€๋ จํ•˜์—ฌ ์—ฌ๋Ÿฌ ์ฆ์ƒ์ด ๋‚˜ํƒ€๋‚œ๋‹ค: weakness(ํ—ˆ์•ฝ), pale mucous membranes(์ ๋ง‰ ์ฐฝ๋ฐฑ), lethargy(๋ฌด๊ธฐ๋ ฅ)

5. Renal Failure and End-Stage Kidney

* โ€œEnd-stage kidneyโ€ ๋ผ๋Š” ํ‘œํ˜„์€ ํ˜•ํƒœํ•™์  ๋ช…๋ช…์ด๋‹ค. โ€˜Renal Failureโ€™๋Š” ์œก์•ˆ ํŒ๋‹จ ์ „์— ํŒ๋‹จ ๊ฐ€๋Šฅ(BUNโ†‘ & Creatinineโ†‘ โ‡’ Renal failure).

์‹ ๋ถ€์ „์˜ ์ง„๋‹จ์—์„œ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์ง€ํ‘œ๋Š” BUN & Creatinine

  • BUN : urea์—์„œ ๋งŒ๋“ค์–ด์ ธ ๊ฐ„์—์„œ ๋Œ€์‚ฌ๋œ ์งˆ์†Œ ํ™”ํ•ฉ๋ฌผ. ํ˜ˆ์ค‘ ๋†๋„๋ฅผ ํ†ตํ•ด ์‹ ์žฅ ๊ธฐ๋Šฅ ํ‰๊ฐ€๋ฅผ ํ•  ์ˆ˜ ์žˆ๋‹ค. (์ •์ƒ์ ์œผ๋กœ ๋Œ€๋ถ€๋ถ„ ๋ฐฐ์ถœ๋˜์–ด์•ผ ํ•˜๋Š”๋ฐ, ํ˜ˆ์ค‘ ๋†๋„๊ฐ€ ๋†’์œผ๋ฉด ์‹ ์žฅ์˜ ์—ฌ๊ณผ ๊ธฐ๋Šฅ์ด ์ •์ƒ์ ์ด์ง€ ์•Š์€ ๊ฒƒ.)
    • ์‹์ด, ์ถœํ˜ˆ, ๊ฐ„ ๊ธฐ๋Šฅ, ํƒˆ์ˆ˜ ์—ฌ๋ถ€์— ๋ฏผ๊ฐํ•˜๊ฒŒ ์˜ํ–ฅ์„ ๋ฐ›๋Š”๋‹ค. (History taking์ด ์ค‘์š”ํ•˜๋‹ค)
    • ์ •์ƒ ๋ฒ”์œ„๋Š” 10-30mg/dL (dogs), 15-35mg/dL (cats)
    • generalํ•œ azotemia marker(์ƒ์Šนํ•˜๋ฉด azotemia).
  • Creatinine : ๊ทผ์œก ๋Œ€์‚ฌ์˜ ๋ถ€์‚ฐ๋ฌผ. GFR, ์ฆ‰ ์‚ฌ๊ตฌ์ฒด๊ธฐ๋Šฅ(์—ฌ๊ณผ์œจ) ํ‰๊ฐ€์— ์ข€ ๋” ํŠน์ด์ ์ธ ๋งˆ์ปค.

BUN์€ ์–ด๋””์— ์ƒ๊ด€์žˆ๋“  generalํ•˜๊ฒŒ ๋†’๋‹ค. / Creatinine์€ ์‚ฌ๊ตฌ์ฒด ๊ธฐ๋Šฅ์— ๋”ฐ๋ผ ๋‹ค๋ฅด๋‹ค โ†’ ๋น„์œจ๋กœ ํ‰๊ฐ€ ๊ฐ€๋Šฅ.

  • Prerenal : ์‚ฌ๊ตฌ์ฒด ๋ฌธ์ œ๊ฐ€ ์•„๋‹ˆ๋ผ ํ˜ˆ์•ก๋Ÿ‰ ์ž์ฒด๊ฐ€ ์ค„๊ฑฐ๋‚˜, ํƒˆ์ˆ˜๊ฐ€ ์‹ฌํ•˜๊ฑฐ๋‚˜ ํ•œ ๊ฒฝ์šฐ - BUN์€ ์ƒ์Šนํ•˜์ง€๋งŒ, creatinine์€ ๋น„๊ต์  ์ •์ƒ.
  • Renal : BUN & Creatinine ๋‘˜ ๋‹ค ์ƒ์Šน. (BUN/Creatinine = ~10-20:1)
  • Postrenal : ์š”๊ด€, ๋ฐฉ๊ด‘, ์š”๋„์˜ ๋ฌธ์ œ. (Ratio๋Š” ์ข€ ๋” ๋‹ค์–‘ํ•œ ๋น„์œจ๋กœ ์žกํžŒ๋‹ค.)

Key Concepts

  • Acute vs. Chronic Renal Failure : definitions & causes
  • Pathogenesis of renal dysfunction :
    • filtration โ†“ (์‚ฌ๊ตฌ์ฒด ๋ฌธ์ œ), tubular back-leak (์„ธ๋‡จ๊ด€ ๋ฌธ์ œ), vasoconstriction (์ „์‹ ์  ๋ฌธ์ œ)
  • Clinical consequences (์ž„์ƒ์ ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฐ๊ณผ) : uremia, polyuria(๋‹ค๋‡จ), electrolyte imbalance(์ „ํ•ด์งˆ ๋ถˆ๊ท ํ˜•)
    • polyuria/polydypsia(๋‹ค์Œ๋‹ค๋‡จ) ์ฆ์ƒ โ†’ โ‘  ์‹ ์žฅ ๊ธฐ๋Šฅ ๋ฌธ์ œ, โ‘ก ๋‚ด๋ถ„๋น„ ๊ธฐ๋Šฅ ๋ฌธ์ œ ์ˆœ์œผ๋กœ ๊ณ ๋ คํ•œ๋‹ค.
    • ํ˜ˆ์•ก๊ฒ€์‚ฌ, ์š”๊ฒ€์‚ฌ๊ฐ€ ์ค‘์š”ํ•˜๋‹ค.
  • End-stage kidney : morphologic changes, sclerosis, fibrosis
    • BUN, creatinine, azotemia ์ด๋Ÿฐ ๊ฑด ํ˜ˆ์•ก๊ฒ€์‚ฌ์—์„œ ๋ณด๋Š” ๊ฑฐ๊ณ , end-stage kidney๋Š” ํ˜•ํƒœํ•™์ ์œผ๋กœ ํŒ๋‹จํ•˜๋Š” ๊ฒƒ.
    • ์‹ ์žฅ์˜ 70-75% ์ด์ƒ ๋ง๊ฐ€์ง€๋ฉด ํ˜•ํƒœํ•™์  ์ง„๋‹จ๋ช…์œผ๋กœ์จ โ€œEnd-stage kidneyโ€๋ผ๊ณ  ํ•  ์ˆ˜ ์žˆ๋‹ค.
  • Uremic sequelae (uremia์— ๋”ฐ๋ผ ์ƒ๊ธธ ์ˆ˜ ์žˆ๋Š” ๋ถ€๊ฐ€์ ์ธ ์ž„์ƒ ์ฆ์ƒ๋“ค) :
    • Ulcerative stomatitis(๊ถค์–‘์„ฑ ๊ตฌ๋‚ด์—ผ), pulmonary edema(ํ๋ถ€์ข…), soft tissue mineralization

โœด๏ธ ์‹ ๋ถ€์ „์˜ ์ •์˜์™€ ์œ ํ˜•

  • ์‹ ๋ถ€์ „ (renal failure) = ์‹ ์žฅ์˜ ๊ธฐ๋Šฅ์ด ์ •์ƒ์ ์œผ๋กœ ์ด๋ฃจ์–ด์ง€์ง€ ๋ชปํ•˜๋Š” ๊ฒƒ (loss of kiney function sufficient to impair homeostasis)
  • ์‹ ๋ถ€์ „์€ ๊ธ‰์„ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜๋„, ๋งŒ์„ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ๋„ ์žˆ๋‹ค.
    • ๊ธ‰์„ฑ (Acute renal failure) : ์ž ์žฌ์ ์œผ๋กœ๋Š” ํšŒ๋ณต์ด ๊ฐ€๋Šฅํ•˜๋‹ค.
    • ๋งŒ์„ฑ (Chronic renal failure) : ์ง„ํ–‰์„ฑ, ์›๋ž˜๋Œ€๋กœ ๋˜๋Œ์•„๊ฐ€๊ธฐ ์–ด๋ ต๋‹ค.
  • โ€˜Uremiaโ€™๋Š” ํ˜ˆ์ค‘ ๋…์„ฑ ๋Œ€์‚ฌ ์‚ฐ๋ฌผ์˜ ์ถ•์ ์œผ๋กœ ์ธํ•ด ์ž„์ƒ์ ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ์—ฌ๋Ÿฌ ์ฆ์ƒ์„ ์ข…ํ•ฉํ•œ ์šฉ์–ด.

Azotemia (์งˆ์†Œํ˜ˆ์ฆ)Uremia (์š”๋…์ฆ)
ํ˜ˆ์•ก์ˆ˜์น˜์ƒ ์งˆ์†Œ์„ฑ ๋…ธํ๋ฌผ(BUN, Creatinine)์˜ ์ƒ์Šนํ˜ˆ์•ก์˜ ๋ณ€ํ™”๋ฅผ ๋™๋ฐ˜,
๋…์„ฑ ๋Œ€์‚ฌ์‚ฐ๋ฌผ์ด ์ถ•์ ๋˜์–ด ์ „์‹ ์— ์˜ํ–ฅ์„ ์ฃผ๋Š” ์ž„์ƒ ์ฆํ›„๊ตฐ
ํšŒ๋ณต์ด ๊ฐ€๋ŠฅํšŒ๋ณต ๊ฐ€๋Šฅ์„ฑ์ด ๋ณ„๋กœ ์—†์Œ
์ข…์ข… ์ฆ์ƒ์ด ์—†๊ฑฐ๋‚˜ mildํ•  ์ˆ˜ ์žˆ๋‹ค.๊ตฌํ† , ์‹์š•๋ถ€์ง„, ๊ตฌ์ทจ, ๊ตฌ๊ฐ• ๊ถค์–‘, ์ฒด์ค‘ ๊ฐ์†Œ, ๋ฌด๊ธฐ๋ ฅ ๋“ฑ
Biochemical abnormalityClinical condition (์ž„์ƒ ์ฆ์ƒ์ด ๋‚˜์˜ฌ ๋•Œ๋งŒ ์“ฐ๋Š”)
์‹ ์žฅ ๊ธฐ๋Šฅ์žฅ์•  ์ดˆ๊ธฐ์— ๋ฐœ์ƒ์‹ ๋ถ€์ „์ด ์‹ฌํ•ด์ง„ ํ›„๊ธฐ์— ๋ฐœ์ƒ
BUN โ†‘, Creatinine โ†‘Azotemia plus clinical signs
  • Azotemia - ํ˜ˆ์ฒญํ™”ํ•™์  ์ด์ƒ ์†Œ๊ฒฌ(ํ˜ˆ์•ก๊ฒ€์‚ฌ์ƒ). ๊ธ‰์„ฑ์ผ ๋•Œ๋„, ๋งŒ์„ฑ์ผ ๋•Œ๋„ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค.
  • Uremia - ๋งŒ์„ฑ์œผ๋กœ ์ง„ํ–‰๋œ ๋ง๊ธฐ ํ™˜์ž์—์„œ ๋‚˜ํƒ€๋‚˜๊ณ , ์ž„์ƒ์ ์ธ ์ƒํƒœ๋ฅผ ๋งํ•œ๋‹ค. (2์ฐจ์ ์œผ๋กœ ๊ตฌ๊ฐ• ์—ผ์ฆ, mineralization์ด ์œ ๋ฐœ๋  ๋•Œ)

BUN & Creatinine์ด ๋†’์•„์ง„ ํ™˜์ž A์™€, ์กฐ๊ธˆ๋งŒ ๋†’์•„์ง„ ํ™˜์ž B โ‡’ BUN/Creatinine ์ˆ˜์น˜๊ฐ€ uremia ํŒ๋‹จ์˜ ๊ฒฐ์ •์  ๊ทผ๊ฑฐ๊ฐ€ ๋˜์ง€ ์•Š๋Š”๋‹ค.

1) Acute Renal Failure (ARF)

[ ์›์ธ ]

  • Prerenal : ํ˜ˆ๋ฅ˜๋Ÿ‰ ๊ฐ์†Œ (์ €ํ˜ˆ๋Ÿ‰์„ฑ ์‡ผํฌ, ํƒˆ์ˆ˜ ๋“ฑ)

  • Renal : nephrotoxins (์‹ ๋…์„ฑ ๋ฌผ์งˆ), ischemia (์‹ ์žฅ์œผ๋กœ ๋“ค์–ด์˜จ ํ˜ˆ๊ด€์˜ ํŽ˜์ƒ‰), glomerulonephritis

  • Postrenal : ํ์ƒ‰ (์š”๊ฒฐ์„, TCC, ureter๋‚˜ urethra์˜ ์ข…์–‘ ๋“ฑ)

  • Hallmark | oliguria(ํ•๋‡จ) or anuria(๋ฌด๋‡จ) with azotemia

[ Pathogenesis ]

  • Filtration failure : ์—ฌ๊ณผ์œจ(GFR)์ด ๊ฐ์†Œํ•œ๋‹ค.
  • Back-leak : ์„ธ๊ด€์ด ์†์ƒ๋˜์–ด ๋ถ€์‚ฐ๋ฌผ, ์ฃฝ์€ ์„ธํฌ ๋“ฑ์ด ์Œ“์ด๋ฉด โ†’ ์˜ฌ๋ผ๊ฐ€์„œ ๊ฐ„์งˆ ๋“ฑ์—๋„ ์˜ํ–ฅ ์ค„ ์ˆ˜ ์žˆ๋‹ค.
  • Intraluminal obstruction : ๋‚ด๊ฐ• ์–ด๋”˜๊ฐ€๊ฐ€ ๋ง‰ํž ์ˆ˜ ์žˆ๋‹ค. (์„ธ๋‡จ๊ด€ ํ๋ฆ„ ๋ง‰ํž˜)
  • Vasoconstriction : ํ˜ˆ๊ด€ ์ˆ˜์ถ•์œผ๋กœ ์ธํ•ด perfusion ๊ฐ์†Œ
  • ์ผ์ฐ ํŒŒ์•…ํ•˜๊ณ  ๋ณด์ถฉํ•˜๋Š” ๊ฒƒ์ด ํšŒ๋ณต์˜ ์ค‘์š”ํ•œ ์š”์†Œ์ด๋‹ค !! (๋งŒ์„ฑํ™”๋กœ ์ด์–ด์ง€๋ฉด ๋น„๊ฐ€์—ญ์ ์œผ๋กœ โ€˜์ง„ํ–‰โ€™๋˜์–ด์„œ, ๊ณ„์† ๋‚˜๋น ์ง„๋‹ค.)

2) Chronic Renal Failure (CRF)

  • ๋น„๊ฐ€์—ญ์ , ์ง„ํ–‰์„ฑ nephron lossd
  • Endpoints : glomemrulonephritis, chronic TIN, glomerular amyloidosis โ†’ ์ด๋Ÿฐ ๊ฒŒ ๋ณด์ด๋ฉด ์กฐ๊ธˆ ๋Šฆ์€ ๋‹จ๊ณ„.
  • ์ž„์ƒ ์ฆ์ƒ : ๋‹ค๋‡จ, ์ฒด์ค‘์†Œ์‹ค, ๋นˆํ˜ˆ(โ† EPO ๊ฐ์†Œ), ๊ตฌํ† , ๊ตฌ์ทจ
  • ์ƒํ™”ํ•™์ ์œผ๋กœ๋Š”
    • azotemia
    • hyperphosphatemia (โ†’ calcium phosphate๋ฅผ ํ˜•์„ฑ, ๊ณ„์† ๋ˆ„์ ๋˜์–ด soft tissue mineralization)
    • metabolic acidosis (์žฌํก์ˆ˜์™€ ๋ฐฐ์ถœ ๋ฌธ์ œ๋กœ ๋Œ€์‚ฌ์„ฑ ์‚ฐ์ฆ)

3) Systemic Effects of Uremia

End-stage kidney์™€ ์—ฐ๊ด€๋˜์–ด uremia๊ฐ€ ๋‚˜ํƒ€๋‚ฌ์„ ๋•Œ, ์—ฌ๋Ÿฌ ๊ฐ€์ง€ ์ „์‹ ์„ฑ ๋ฌธ์ œ๊ฐ€ ๋‚˜ํƒ€๋‚œ๋‹ค.

  • ์†Œํ™”๊ธฐ๊ณ„ : ulcerative stomatitis, vomiting, diarrhea
  • ์‹ฌํ˜ˆ๊ด€๊ณ„ : fibrinous pericarditis, pulmonary edemia
  • ๊ทผ๊ณจ๊ฒฉ๊ณ„ : renal osteodystrophy
  • ํ˜ˆ์•กํ•™์  : non-regenerative anemia, platelet dysfunction

Nonrenal Lesions of Uremia

  • Pulmonary edema (Increased vascular permeability)
  • Fibrinous pericarditis (Increased vascular permeability)
  • Ulcerative and hemorrhagic gastritis (Ammonia secretion & vascular necrosis)
  • Ulcerative and necrotic stomatitis (Ammonia secretion in saliva & vascular necrosis)
  • Atrial and aortic thrombosis (Endothelial & subendothelial damage)
  • Hypoplastic anemia (โ†‘ erythrocyte fragility & โ†“ erythropoietin production)
  • Soft-tissue mineralization (Altered Caโ€“P metabolism; stomach, lungs, pleura, kidneys)
  • Fibrous osteodystrophy (Altered Caโ€“P metabolism)
  • Parathyroid hyperplasia (Altered Caโ€“P metabolism)
๋น„์‹ ์„ฑ ์š”๋…์ฆ ๋ณ‘๋ณ€ ๊ธฐ์ „
ํ˜ˆ๊ด€ ํˆฌ๊ณผ์„ฑ ์ฆ๊ฐ€
Pulmonary edema, Fibrinous pericarditis
(๋…์„ฑ ๋ฌผ์งˆ์ด ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ ์†์ƒ, ๋‚ดํ”ผ์„ธํฌ๋ผ๋ฆฌ ์—ฐ๊ฒฐ๋˜๊ฒŒ ํ•˜๋Š” ๋ฌผ์งˆ๋“ค๋„ ๋…์†Œ์— ์˜ํ•ด ๋Š์–ด์ง โ†’ ํ˜ˆ๊ด€ํˆฌ๊ณผ์„ฑ ์ฆ๊ฐ€)
์•”๋ชจ๋‹ˆ์•„ ๋ถ„๋น„ + ํ˜ˆ๊ด€ ๊ดด์‚ฌ
Ulcerative and hemorrhagic gastritis, Ulcerative and necrotic stomatitis
(ammonia ๊ฐ™์€ ๋…์„ฑ ๋Œ€์‚ฌ๋ฌผ์งˆ์ด ํ˜ˆ๊ด€๋‚ดํ”ผ์„ธํฌ๊ณผ ์œ„์ ๋ง‰ ์„ธํฌ๋ฅผ ์†์ƒ์‹œ์ผœ ์œ„๊ถค์–‘, ์œ„์—ผ, ์ถœํ˜ˆ ๋“ฑ์„ ์œ ๋ฐœ)
+ ์•„์ฃผ ์‹ฌํ•œ ๊ตฌ์ทจ๋„ ์š”๋…์ฆ ์˜์‹ฌ ์†Œ๊ฒฌ
์ ํ˜ˆ๊ตฌ ๋ฌธ์ œ
Hypoplastic anemia (๋น„์žฌ์ƒ์„ฑ ๋นˆํ˜ˆ)
(์š”๋…์ฆ์˜ toxin์ด RBC๋“ค์„ ํŒŒ๊ดดํ•˜๊ณ  lifespan์„ ์ค„์ž„ + EPO(erythropoietin) ๋ถ„๋น„๊ฐ€ ๊ฐ์†Œ)
ํ˜ˆ๊ด€ ์†์ƒ
Thrombosis
Ca-P ๋Œ€์‚ฌ ์ด์ƒ
- Soft-tissue mineralization (โ† calcium-phosphate๋ฅผ ๊ณ„์† ํ˜•์„ฑํ•ด์„œ ์œ„, ํ, ์žฅ๋ง‰ ๋“ฑ์— ์นจ์ฐฉ)
- Fibrous osteodystrophy (๋ผˆ๋Š” ๊ณ„์† ์นผ์Š˜์„ ์žƒ์–ด๋ฒ„๋ฆผ โ†’ ๊ฒฐํ•ฉ์กฐ์ง์ด ์—„์ฒญ ๋ฐœ๋‹ฌ, osteoblast๋„ ๊ณ„์† ์ž‘๋™ํ•˜์ง€๋งŒ ๋ฏธ์„ฑ์ˆ™ํ•œ ๊ณจ์กฐ์ง ํ˜•์„ฑ)
- Parathyroid hyperplasia (์œ ๋ฆฌ ์นผ์Š˜ ๋†๋„๋Š” ๊ณ„์† ์ค„์–ด๋“ค๊ธฐ ๋•Œ๋ฌธ์—, ๋ถ€๊ฐ‘์ƒ์„ ์—์„œ ํ˜ˆ์ค‘ ์นผ์Š˜ ๋†๋„๋ฅผ ๋งž์ถ”๊ธฐ ์œ„ํ•ด ์—ด์‹ฌํžˆ ์ผ์„ ํ•จ)

ํ‘œ๋Š” ๋‹ค ์•Œ์•„์•ผ ํ•จ! ๋งŒ์„ฑ ์‹ ๋ถ€์ „ ํ™˜์ž์—์„œ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋Š” ์ฆ์ƒ. Kidney์˜ ์ •์ƒ ๊ธฐ๋Šฅ์— ๊ธฐ๋ฐ˜ํ•˜์—ฌ ์•ˆ ๋ณด๊ณ ๋„ ์ž‘์„ฑํ•  ์ค„ ์•Œ์•„์•ผ.


ํ™˜์ž์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” Uremia ๊ด€๋ จ ์ „์‹  ์ฆ์ƒ๋“ค.

4) End-Stage Kidney

[ ํ˜•ํƒœํ•™์  ์†Œ๊ฒฌ ]

  • ์ฐฝ๋ฐฑํ•˜๊ณ  ์œ„์ถ•๋˜๊ณ  ์„ฌ์œ ํ™”. (pale, shrunken, fibrotic; ๋‹ค fibrosis ํŠน์ง•)
  • ์‹ ์žฅ ์ „๋ฐ˜์ ์œผ๋กœ ์‚ฌ๊ตฌ์ฒด ๊ฒฝํ™”, ๊ฐ„์งˆ ์„ฌ์œ ํ™”, ์„ธ๋‡จ๊ด€ ์œ„์ถ• (widespread glomerulosclerosis, interstitial fibrosis, tubular atrophy)
    • ์‚ฌ๊ตฌ์ฒด๋Š” ๋Œ€๋ถ€๋ถ„ ์ฝœ๋ผ๊ฒ ์„ฑ๋ถ„์œผ๋กœ ๋Œ€์ฒด๋˜์–ด ์žˆ๋‹ค.
  • arterial thickening, periglomerular fibrosis
  • corticomedullary distinction์˜ ์†Œ์‹ค

[ Pathogenesis ]

  • ์ฒ˜์Œ ์›์ธ๊ณผ ์ƒ๊ด€์—†์ด, ์•„๋ž˜ ๊ณผ์ •์œผ๋กœ ์ง„ํ–‰๋œ๋‹ค.
    • Proteinuria โ†’ tubular damage
      (๋‹จ๋ฐฑ๋‡จ = โ‘  ์‚ฌ๊ตฌ์ฒด๊ฐ€ ๋ง๊ฐ€์กŒ๋‹ค + โ‘ก ์„ธ๋‡จ๊ด€์„ ๋ง๊ฐ€๋œจ๋ฆด ์ˆ˜ ์žˆ๋‹ค โ‡’ ์ฃผ๋ณ€ ๊ฐ„์งˆ ์—ผ์ฆ ์œ ๋ฐœ, ..)
    • Interstitial inflammation โ†’ fibrosis
    • Ischemia from vascular compromise
  • Progressiveํ•˜๊ณ  irreversibleํ•˜๋‹ค.

[ Outcomes and Prognosis ]

  • ๋ณดํ†ต Uremia์— ๋™๋ฐ˜๋˜๋Š” ์ „์‹  ์ฆ์ƒ๋“ค๋กœ ์ฃฝ๊ฑฐ๋‚˜ ์•ˆ๋ฝ์‚ฌ ใ… .ใ… 
  • ํˆฌ์„(dialysis), ์‹ ์žฅ์ด์‹(renal transplantation)์˜ ๋ฐฉ๋ฒ•์ด ์žˆ์ง€๋งŒ ์•„์ง ํ˜„์‹ค์ ์œผ๋กœ ์–ด๋ ต๊ณ , ๋งŽ์ง€ ์•Š๋‹ค.
  • ๋Œ€๋ถ€๋ถ„ supportive care, ์ฒœ์ฒœํžˆ ๋‚˜๋น ์ง€๊ฒŒ ํ•˜๋Š” management๊ฐ€ ์ตœ์„ .

6. Lower Urinary Tract Disorders

Key Concepts

  • Cystitis (๋ฐฉ๊ด‘์—ผ) :
    • Acute / chronic (๋ชจ๋“  ์—ผ์ฆ์€ ๊ธ‰์„ฑ๊ณผ ๋งŒ์„ฑ)
    • hemorrhagic or not
    • emphysematous forms (์ข…์–‘์ฒ˜๋Ÿผ ๋ณด์ผ ์ˆ˜ ์žˆ๋Š” ํŠน์ง•์ ์ธ ํ˜•ํƒœ)
  • Common pathogens : ์„ธ๊ท ์„ฑ ๊ฐ์—ผ ์ค‘์š” (E. coli, Corynebacterium renale, Proteus)
  • Urolithiasis (์š”๋กœ ๊ฒฐ์„; ๋ฐฉ๊ด‘๊ฒฐ์„, ์š”๊ด€๊ฒฐ์„ ๋“ฑ) : ํ†ต์ฆ์ด ์—„์ฒญ ํฌ๋‹ค.. ํ•ด๋ถ€ํ•™์  ์œ„์น˜์ƒ ํ†ต์ฆ ๋ถ€์œ„๊ฐ€ ๋“ฑ์ชฝ์ด ๋œ๋‹ค.
    • Postrenal azotemia์˜ ์ฃผ์š” ์›์ธ.
  • Pyelonephritis (์‹ ์šฐ์‹ ์—ผ) : ์‹ ์šฐ - ๊ฐ€์žฅ digital ๋ถ€์œ„. ์ฃผ๋กœ ํ•˜๋ถ€ ๋น„๋‡จ๊ธฐ๊ณ„์— ์ƒ๊ธด ์—ผ์ฆ์ด ์ƒํ–‰์„ฑ์œผ๋กœ ํŒŒ๊ธ‰๋ผ์„œ ์ƒ๊ธด๋‹ค.

Anatomy & Defense

  • ํ•˜๋ถ€ ๋น„๋‡จ๊ธฐ๋Š” ์‹ ์žฅ ์ดํ›„, ์š”๊ด€(ureters), ๋ฐฉ๊ด‘(urinary bladder), ์š”๋„(urethra) ๋ฅผ ํฌํ•จํ•œ๋‹ค.
  • ํ•˜๋ถ€ ๋น„๋‡จ๊ธฐ๊ณ„๋Š” ํ•ญ์ƒ sterileํ•œ ๋ฌด๊ท  ์ƒํƒœ๋ฅผ ์œ ์ง€ํ•˜๊ณ  ์žˆ๋‹ค.
    • ์š”๊ฒ€์‚ฌ์—์„œ ์„ธ๊ท  ๊ฒ€์ถœ = ๋น„์ •์ƒ์  ์ƒํ™ฉ
  • Disruption(์š”์˜ ์ •์ฒด) โ†’ ๊ฐ์—ผ, ์—ผ์ฆ์„ ์ด‰๋ฐœํ•˜๋Š” ์ค‘์š”ํ•œ ์š”์†Œ๊ฐ€ ๋œ๋‹ค.
    • Obstruction์€ ๋‹จ์ˆœ ์ •์ฒด๊ฐ€ ์•„๋‹ˆ๋ผ 2์ฐจ์ ์ธ ์—ผ์ฆ, ๊ฐ์—ผ์„ ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ๋Š” ์œ„ํ—˜ํ•œ ์ƒํ™ฉ!
  • FLUTD (Feline Lower Urinary Tract Disease) - ์œ ๋ช…ํ•˜๊ณ  ์ค‘์š”ํ•œ ์งˆํ™˜.

1) Cystitis

๋ฐฉ๊ด‘์—ผ - ๋ฐฉ๊ด‘ ์งˆํ™˜ ์ค‘ ๊ฐ€์žฅ ํ”ํ•œ ํ˜•ํƒœ์ด๋‹ค.

[ Etiology ]

  • ์„ธ๊ท  ๊ฐ์—ผ์ด ๋Œ€๋ถ€๋ถ„์ด๊ณ , ๋œ ํ”ํ•˜์ง€๋งŒ ๋ฐ”์ด๋Ÿฌ์Šค ๊ฐ์—ผ๋„ ์žˆ์„ ์ˆ˜ ์žˆ๋‹ค.
    • Bacterial (E. coli, Proteus, Corynebacterium renalis)
    • Viral (adenovirus)
  • ํ˜น์€ trauma(์™ธ์ƒ์„ฑ), uroliths(์š”๋กœ ๊ฒฐ์„) ๋“ฑ
    • ์š”๋กœ ๊ฒฐ์„์— ์˜ํ•ด ์š”๋„๊ฐ€ ๋ง‰ํžˆ๋ฉด โ†’ ๊ฐ์—ผ์— ์ทจ์•ฝํ•œ ์ƒํƒœ๊ฐ€ ๋œ๋‹ค.

[ Types ]

  • ํŠนํžˆ ์„ธ๊ท  ๊ฐ์—ผ์— ์˜ํ•ด: Acute suppurative cystitis
  • ๋งŒ์„ฑ์œผ๋กœ ์ง„ํ–‰๋  ๊ฒฝ์šฐ: Chronic cystitis with lymphoplasmacytic infiltration
  • ํŠน์ • ์›์ธ์— ์˜ํ•ด: Hemorrhagic cystitis
  • ์ผ๋ถ€ ์„ธ๊ท ์˜ ๊ฒฝ์šฐ: Emphysematous cystitis (gas-producing bacteria)
    • ๋ฐฉ๊ด‘ ๋‚ด์—์„œ ์ฆ์‹ํ•˜๋ฉด์„œ ๊ฐ€์Šค๋ฅผ ๋งŒ๋“ ๋‹ค โ†’ ๋ฐฉ๊ด‘ ์ ๋ง‰์ด ์ข…์–‘์ฒ˜๋Ÿผ ์šธํ‰๋ถˆํ‰ํ•ด์ง„๋‹ค.์œก์•ˆ์ ์œผ๋กœ TCC์™€ ๊ฐ€์žฅ ํ—ท๊ฐˆ๋ฆฐ๋‹ค. TCC๋Š” ๋ฐฉ๊ด‘์‚ผ๊ฐ์—์„œ ๊ฐ€์žฅ ํ˜ธ๋ฐœํ•˜๊ณ , ์ง„ํ–‰๋˜๋ฉด ๋ฐฉ๊ด‘ ์ „์ฒด์—์„œ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ๋Š”๋ฐ ์šธํ‰๋ถˆํˆญํ•œ ๋Œ์ถœ์„ฑ ๋ณ‘๋ณ€์ด ๋น„์Šทํ•ด์„œ ๊ฐ๋ณ„์ด ๊ผญ ํ•„์š”ํ•˜๋‹ค.

[ Pathogenesis]

  • ์™ธ๋ถ€๋กœ๋ถ€ํ„ฐ ์œ ์ž…๋œ ์„ธ๊ท ์ด urethra(์š”๋„)์— ๋ฌธ์ œ๋ฅผ ์ผ์œผํ‚ค๊ณ , ๊ฑฐ๊ธฐ์„œ ์ƒํ–‰์„ฑ์œผ๋กœ ์ง„ํ–‰๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. (์ •์ƒ์ ์œผ๋กœ ์˜ค์คŒ์€ ๋ฌด๊ท  ์ƒํƒœ๋ฅผ ์œ ์ง€ํ•˜๊ณ  ์žˆ๊ธฐ ๋•Œ๋ฌธ์— proximal ์ชฝ์—์„œ ๋ฌธ์ œ๊ฐ€ ๋˜๋Š” ์ผ์€ ํ”ํ•˜์ง€ ์•Š๋‹ค)
  • ์ด‰๋ฐœ ์š”์ธ์œผ๋กœ๋Š”
    • Obstruction (์š”๋กœ ๊ฒฐ์„์— ์˜ํ•œ ํ์ƒ‰)
    • Catheterization (๋ฌด๊ท ์ด ๊นจ์ง„ ์นดํ…Œํ„ฐ ์‚ฝ์ž…; iatrogenic ๋˜๋Š” ์‚ฝ์ž… ๊ณผ์ •์—์„œ ์ ๋ง‰ ์†์ƒ)
    • Glucosuria (diabetes) (์š” ์ค‘ ๋‹น์˜ ๋†๋„๊ฐ€ ๋†’์•„์ง€๋ฉด ์„ธ๊ท ์ด ์ฆ์‹ํ•˜๊ธฐ ์‰ฌ์›€)
    • Immunosuppression (์ž˜ ์–ต๋ˆŒ๋ ค ์žˆ๋˜ ์„ธ๊ท ์ด ์ฆ์‹)
  • ๋ฐฉ๊ด‘์—ผ์€ ๋งค์šฐ ํฐ ๊ณ ํ†ต์„ ์œ ๋ฐœํ•˜๊ณ , hematuria(ํ˜ˆ๋‡จ), stranguria(๋ฐฐ๋‡จํ†ต) ๋“ฑ์ด ์ƒ๊ธธ ์ˆ˜ ์žˆ๋‹ค.
  • ๋งŒ์„ฑํ™”๋  ๊ฒฝ์šฐ ์ ๋ง‰ ์ƒํ”ผ์„ธํฌ์˜ ๊ณผ์ฆ์‹์ด ๊ด€์ฐฐ๋œ๋‹ค. โ‡’ Brunnโ€™s nest (์‚ฌ๋žŒ์—์„œ๋Š” TCC์˜ ์ „์•” ๋ณ‘๋ณ€์œผ๋กœ ์•Œ๋ ค์ ธ ์žˆ๋‹ค)

2) Urolithiasis (Urinary stone)

  • ์›๋ž˜๋Œ€๋กœ๋ผ๋ฉด ์ด์˜จ ์ƒํƒœ, ๋ฐฐ์ถœ๋˜๋Š” ์ƒํƒœ์ด์ง€๋งŒ ํŠน์ • ์›์ธ์— ์˜ํ•ด ๋Œ(๊ฒฐ์„)์ด ๋  ์ˆ˜ ์žˆ๋‹ค.
    • Diet - high phosphate or magnesium (์ธ์‚ฐ, ๋งˆ๊ทธ๋„ค์Š˜์„ ๋„ˆ๋ฌด ๋งŽ์ด ์„ญ์ทจ)
    • Dehydration (์†Œ๋ณ€ ๋‚ด fluid ํ•จ๋Ÿ‰์ด ๋งค์šฐ ๋–จ์–ด์ ธ ๋†์ถ•๋จ)
    • Urinay pH (์š”์˜ pH๊ฐ€ ๋ฐ”๋€Œ์—ˆ์„ ๋•Œ)
    • Infections altering solubility (๊ฐ์—ผ์„ฑ ์›์ธ)
  • ํ˜•ํƒœ์™€ ๊ตฌ์„ฑ์— ๋”ฐ๋ผ struvite, calcium oxalate, urate ๋“ฑ์ด ์žˆ๋‹ค.

  • ์–ด๋–ป๊ฒŒ ์—†์•จ ๊ฒƒ์ธ๊ฐ€? ์ž‘์€ ์š”๋„๋Š” ์ž‘์€ ๊ฒฐ์„์œผ๋กœ๋„ ํ์ƒ‰๋  ์ˆ˜ ์žˆ๋‹ค. โ†’ ์™ธ๋ถ€ ์ƒ์‹๊ธฐ์—์„œ ์ง„์ž…ํ•ด์„œ ์ˆ˜์••์œผ๋กœ ๋ฐ€์–ด๋‚ธ๋‹ค. โ†’ ์—ญ์œผ๋กœ ๋ฐ€์–ด์˜ฌ๋ ค์„œ ๋ฐฉ๊ด‘ ์ค‘์— ๋– ๋Œ์•„๋‹ค๋‹ˆ๊ฒŒ ํ•œ๋‹ค(๋ฐฉ๊ด‘์€ ์ž‘์€ ํ•œ๋‘ ๊ฐœ์˜ ๊ฒฐ์„์œผ๋กœ ๋ง‰ํžˆ์ง€ ์•Š์œผ๋ฏ€๋กœ).

  • ๊ฒฐ๊ณผ

    • Irritation, ulceration, obstruction (๊ฑฐ์นœ ๊ฒฐ์„์˜ ๊ฒฝ์šฐ ๋น„๋‡จ๊ธฐ ์ ๋ง‰์„ ๊ธ์–ด ์†์ƒ์„ ์ฃผ๊ฑฐ๋‚˜ ๊ถค์–‘์ด ์ƒ๊ธธ ์ˆ˜ ์žˆ๋‹ค.)
    • Hydroureter, hydronephrosis (์š”๊ด€ ํ์ƒ‰ ๋ถ€์œ„์˜ proximal ์ชฝ์€ ๋ถ€ํ’€์–ด์˜ค๋ฅด๊ณ , ๋‡จ๊ฐ€ ๊ณ„์† ๊ณ ์ด๋ฉด์„œ ์‹ ์šฐ ๋ถ€์œ„๊นŒ์ง€ ๋จธ๋ฌธ๋‹ค. ์‹ ์šฐ์— ์ˆ˜๋ถ„์ด ์ถ•์ ๋˜๋ฉด์„œ ๋‚˜๋จธ์ง€ ํ”ผ์งˆ/์ˆ˜์งˆ์„ ์••๋ฐ•ํ•ด์„œ ์‹ค์งˆ์ด ์–‡๊ฒŒ ์ค„์–ด๋“ ๋‹ค. ์‹ ์šฐ์˜ ํ…… ๋นˆ ๋ถ€๋ถ„์ด ์ˆ˜๋ถ„์ด ์ฐจ ์žˆ๋Š” ํ˜•ํƒœ๊ฐ€ ๋œ๋‹ค.)
    • Predisposition to bacterial cystitis and pyelonephritis (๊ฐ์—ผ์— ์˜ํ•ด์„œ ์ƒ๊ธธ ์ˆ˜๋„ ์žˆ์ง€๋งŒ, ์š”๋กœ๊ฒฐ์„์€ ๊ทธ ์ž์ฒด๋กœ ์„ธ๊ท ์„ฑ ๋ฐฉ๊ด‘์—ผ์˜ ์ด‰๋ฐœ ์š”์ธ์ด ๋˜๊ณ , ์‹ฌํ•ด์ง€๋ฉด ์ƒํ–‰์„ฑ์œผ๋กœ ์‹ ์šฐ์‹ ์—ผ๋„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ๋‹ค.)
    • ์ง€์†๋˜๋ฉด postrenal azotemia, ์‹ฌํ•˜๋ฉด ์‚ฌ๋ง๋„ ํ•  ์ˆ˜ ์žˆ๋Š” ์งˆ๋ณ‘์ด ๋œ๋‹ค.

3) Pyelonephritis

7. Urinary Tract Neoplasia

Key Concepts

  • ์••๋„์ ์œผ๋กœ TCC(Transitional cell carcinoma)๊ฐ€ ๋งŽ์ด ์ƒ๊ธด๋‹ค.
    • ๊ฑฐ์˜ ๋Œ€๋ถ€๋ถ„ ์•…์„ฑ์ด๋‹ค.
    • ์š”๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด, ํŠน์ • ์œ ์ „์ž์˜ mutation์ด ๋†’์€์ง€ ํ™•์ธํ•˜๋ฉด ์ •ํ™•ํ•œ ์ง„๋‹จ ๊ฐ€๋Šฅ
  • TCC์™€ ๊ฐ๋ณ„์ด ํ•„์š”ํ•œ ๋‹ค๋ฅธ ์ข…์–‘ : squamous cell carcioma, adenocarcinoma, nephroblastoma
    • adenocarcinoma : ํ•˜๋ถ€ ๋น„๋‡จ๊ธฐ๊ณ„์— adeno- ์„ธํฌ๋Š” ์—†์ง€๋งŒ, renal cell์—์„œ ์œ ๋ž˜ํ•œ ์ข…์–‘์ด ํ•˜๋ถ€ ๋น„๋‡จ๊ธฐ๊ณ„๋กœ ํ™•์žฅ๋  ์ˆ˜ ์žˆ๋‹ค.
  • ๋น„๋‡จ๊ธฐ๊ณ„ ์ข…์–‘ : ๊ฐœ > ๊ณ ์–‘์ด > ๋ฐ˜์ถ”๋ฅ˜ ์ˆœ์œผ๋กœ ๋ฐœ์ƒ์ด ๋†’๋‹ค
  • Paraneoplastic syndromes๊ฐ€ ์žˆ๋‹ค, metastasis ๊ฐ€๋Šฅ์„ฑ์ด ๋†’๋‹ค.
    • TCC๋Š” ์ง„ํ–‰๋„ ๋น ๋ฅด๊ณ  ์ „์ด ๊ฐ€๋Šฅ์„ฑ๋„ ๋†’๊ณ  ์•…์„ฑ๋„๋„ ๋†’๋‹ค. ๋ฐฉ๊ด‘ ์กฐ์ง์—์„  ์–ผ๋งˆ ์•ˆ ๋ณด์ด๋˜ ์ข…์–‘ ์„ธํฌ๋“ค์ด ํ”ผ๋ถ€๋กœ ๋‹ค ์ „์ด๋˜์–ด ์žˆ๊ธฐ๋„ ํ–ˆ์Œ.
  • Kidney : Renal tubular epithelium, transitional epithelium (renal pelvis)
    • Renal adenoma : ์ƒ˜์„ ํ˜•์„ฑํ•˜๋Š” ์ƒํ”ผ์„ธํฌ๋“ค์ด ํ˜•์„ฑ
    • Renal cell carcinoma (RCC)
  • Ureter, Urinary bladder, Urethra : Transitional epithelium
    • Transitional cell carcinoma
    • Squamous cell carcinoma (metaplasia)
  • ์ž„์ƒ ์ฆ์ƒ : ๋‡จ์˜ ํ๋ฆ„์„ ๋ง‰๋Š”๋‹ค โ†’ ํ˜ˆ๋‡จ, obstruction์— ๋”ฐ๋ฅธ 2์ฐจ์  ๊ฐ์—ผ

(์‚ฌ์ง„: Renal adenoma vs. Renal cell carcinoma ์•ž2:๋’ค2, ์•ž1:๋’ค2 ํ™”์‚ดํ‘œ : ์นจ์Šต์ด ์ผ์–ด๋‚จ, invasion / ๊ณ ๋ฐฐ์œจ๋กœ ๋ด๋„ ์•…์„ฑ๋„๊ฐ€ ๋†’์Œ ๋‘˜์„ ๊ตฌ๋ถ„ํ•˜๋Š” ๊ฑด ์นจ์Šต ์œ ๋ฌด๊ฐ€ ์ค‘์š”)

1๏ธโƒฃ Transitional Cell Carcinoma (TCC)

  • TCC(=urothelial cell carcinoma)๋Š” ๋ฐฉ๊ด‘์‚ผ๊ฐ(the bladder trigone) ์—์„œ ์ž˜ ์ƒ๊ธด๋‹ค.
  • ์นจ์Šต๊ณผ ์ „์ด๊ฐ€ ๋งค์šฐ ํ”ํ•˜๋‹ค (๊ตญ์†Œ ๋ฆผํ”„์ ˆ, ํ๊นŒ์ง€)
  • ์ ๋ง‰์ด ๋น„ํ›„๋˜๊ณ , ๋ถˆ๊ทœ์น™ํ•˜๋‹ค. 2์ฐจ์ ์œผ๋กœ ์ ๋ง‰์˜ ๊ถค์–‘๋„ ๊ด€์ฐฐ๋  ์ˆ˜ ์žˆ๋‹ค.

(TCC์‚ฌ์ง„)

2๏ธโƒฃ Others Neoplasmas of the Urinary Tract

  • ์ƒํ”ผ์„ธํฌ ์ข…์–‘

    • Squamous cell carcinoma : ์ €ํ•ญ์„ฑ ์žˆ๋Š” ์„ธํฌ๋กœ ๋ณ€ํ•˜๊ณ ์ž ํ•˜๋Š” metaplasia โ†’ ์ด๊ฒŒ ์ข…์–‘ํ™”๋˜์–ด squamous cell carcinoma (๋น„๋‡จ๊ธฐ์— squamous cell ์—†์ง€๋งŒ, metaplasia ๋•Œ๋ฌธ์— ์ƒ๊ธธ ์ˆ˜ ์žˆ๋‹ค)
    • Adenocarcinoma : ์‹ ์žฅ tubule์—์„œ ์ „์ด๋˜์–ด ์˜ด
    • Nephroblastoma (์–ด๋ฆฐ ๊ฐœ, ๋ผ์ง€)
  • ์ค‘๋ฐฐ์—ฝ ์œ ๋ž˜ ์ข…์–‘

    • Leiomyoma/Leiomyosaracoma (ํ‰ํ™œ๊ทผ ์œ ๋ž˜)
    • Rhabdomyoma/Rhabdomyosarcoma (ํšก๋ฌธ๊ทผ ์œ ๋ž˜)
  • (๋ฐ”๊นฅ์ชฝ์œผ๋กœ ๋ถˆ๊ทœ์น™ํ•˜๋ฉด, ๋ฒฝ์„ ํ˜•์„ฑํ•˜๋Š” ๊ทผ์œก ์ชฝ ์ข…์–‘์ด๊ฒ ๊ตฌ๋‚˜)

3๏ธโƒฃ Lymphoma

๋ฐฉ๊ด‘์—์„œ ์›๋ฐœ lymphoma๋Š” ๋งค์šฐ ๋“œ๋ฌผ๋‹ค. ์‹ ์žฅ์— ์ƒ๊ธด lymphoma๋Š” ์ „์ด๋˜์—ˆ์„ ๊ฐ€๋Šฅ์„ฑ์ด ํฌ๋‹ค.

  • ๊ธธ์„ ๋ง‰์•„์„œ renomegaly,
  • ์ •์ƒ ๋„คํ”„๋ก ์„ ๋Œ€์ฒดํ•˜๊ณ  ์žˆ์œผ๋ฏ€๋กœ renal failure,
  • paraneoplastic hypercalcemia (PTH-rH ๋ถ„๋น„ํ•˜๋Š” ์ข…์–‘ ์ค‘ ํ•˜๋‚˜๊ฐ€ lymphoma)

(์ „์ดํŒจํ„ด) ์Œ€์•Œ์ฒ˜๋Ÿผ ์žˆ๋Š” ํ•˜์–€์ƒ‰ ๊ฒฐ์ ˆ๋“ค, ์–‘์ธก์„ฑ ํŒจํ„ด. โ‡’ ์ „์ด๋œ ์ข…์–‘์ผ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’๋‹ค๋Š” ๊ฒƒ์„ ์•”์‹œ.

Tumor-like lesions
  • Eosinophilic polypoid cystitis : ๋ณผ๋ก๋ณผ๋กํ•œ ํ˜•ํƒœ, ์—ผ์ฆ์— ์˜ํ•ด์„œ๋„ ๋Œ์ถœ๋œ ํ˜•ํƒœ์ผ ์ˆ˜ ์žˆ๋‹ค.
  • Cystitis glandularis
    • Brunnโ€™s nest : ์ ๋ง‰์กฐ์ง์— ์›๋ž˜ ์ƒํ”ผ์„ธํฌ๊ฐ€ ์—†๋Š”๋ฐ, ๋น„์Šทํ•œ ๊ตฌ์กฐ๋ฅผ ๋งŒ๋“ ๋‹ค โ†’๋‹จ์ˆœ ๊ณผ์ฆ์‹์ธ๋ฐ, ์ข…์–‘์˜ ์นจ์Šต๊ณผ ํ—ท๊ฐˆ๋ฆฌ๋Š” ๊ฐ€์žฅ ์œ ๋ช…ํ•œ ๋ณ‘๋ณ€ ์ค‘ ํ•˜๋‚˜. ์ƒํ”ผ์„ธํฌ๊ฐ€ ๋ฐ‘์œผ๋กœ ํŒŒ๊ณ ๋“ค๋“ฏ์ด ์ฆ์‹ํ•ด์„œ ์ƒ๊ธด๋‹ค(invaginations)
      • โ‡’ ์žฅ๊ธฐ์ ์œผ๋กœ ๋ฐฉ๊ด‘์•”์ด ์ƒ๊ธธ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’์•„์ง„๋‹ค- ์‚ฌ๋žŒ์—์„  ๊ทธ๋Ÿฐ๋ฐ, ๋™๋ฌผ์—์„œ๋Š” ์—ฐ๊ตฌ ๊ฒฐ๊ณผ ๋ถ€์กฑ
  • ๋งŒ์„ฑ ๋ฐฉ๊ด‘์—ผ์ผ ๋•Œ ์ƒํ”ผ์„ธํฌ๊ฐ€ ๋งˆ์น˜ ์ข…์–‘์ด๋ž‘ ๋น„์Šทํ•ด ๋ณด์ผ ์ˆ˜ ์žˆ๋‹ค~
Species-Specific Patterns
  • ๊ฐœ : ์••๋„์ ์œผ๋กœ TCC
  • ๊ณ ์–‘์ด : TCC > lymphoma๋„ ์ข…์ข…
  • ์†Œ : TCC
  • ๋ผ์ง€ : nephroblastoma

(260522 ๋ณ‘๋ฆฌ 55๋ถ„ ์ดํ›„ ๋‹ค์‹œ)